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1. INTRODUCTION 
 
1.1. Biological barriers - functions and characteristics 
Biological barriers separate our bodies from the external environment and certain 
protected organs, like the brain, from the systemic circulation. Epithelial and endothelial 
cells form the anatomical basis of these barriers which provide protection from harmful 
agents and pathogens and establish and maintain the homeostasis of body compartments 
(Deli, 2009). Cells of the barriers are connected by tight junctions (TJs) which close the 
intercellular gap and determine the tightness of barriers. These TJs restrict the paracellular 
passage of cells, molecules or ions across epithelial and endothelial barriers and limit the 
penetration of drugs. Therefore, the paracellular permeability is one of the most important 
determinant of drug delivery across biological barriers and enhancing the permeability of 
certain drugs, especially large biopharmaceuticals is a great challenge in pharmaceutical 
research (Ward et al., 2000; Abbott, 2013).  
 
Figure 1. Major biological barriers of the human body. 
 
The main epithelial barriers are the skin, the respiratory surface and the 
gastrointestinal tract (Fig. 1). Dermal epithelium is the least permeable barrier due to its 
anatomical structure, and shows a high, about 5000 Ω × cm2 electrical resistance reflecting 
very low ionic permeability. In comparison, the resistance of small intestinal or proximal 
renal epithelium is typically below 100 Ω × cm2 indicating a more permeable barrier for 
ions (Yu and Turner, 2008). Despite the tightness of the skin as a barrier, transdermal drug 
delivery is a promising field of pharmaceutical research and therapy (Naik et al., 2000; 
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Karande and Mitragotri, 2009). Airway epithelium is another non-invasive administration 
route for drugs to treat systemic disorders. Due to the large surface area (about 160 m
2
 
alveolar surface) and high vascularization of respiratory epithelium, the pulmonary or nasal 
drug administration has a great potential to target the systemic circulation besides local 
effects (Scheuch et al; 2006). The most popular method for drug therapy is the oral 
administration. This route is efficient and safe with good patient compliance. However 
drug absorption in the gastrointestinal tract (GI) is limited by intercellular junctions, and 
the paracellular route is one of the factors determining drug penetration (Deli, 2009). The 
total surface area of the GI tract is approximately 200 m
2
, but the extent of absorption is 
different between its regions (Deli, 2009). The jejunum and ileum show higher drug 
absorption rate compared to buccal and rectal mucosa where the penetration is restricted 
but these are important site for drug administration due to rapid effect in crisis therapy 
(Ward et al., 2000; Deli, 2009). The absorption level and rate depends on the composition 
of cellular membranes, the anatomical structures, the expression pattern of TJ proteins and 
transporters in the cell membrane (Chiba et al., 2008).  
The blood-brain barrier (BBB), a special dynamic interface between the blood and 
the central nervous system (CNS) is formed by endothelial cells. The BBB is composed of 
brain microvascular endothelial cells surrounded by pericytes and astrocytic endfeet. The 
interactions of these cells with microglia and neurons constitute a functional unit, the 
neurovascular unit (Abbott et al., 2010). The BBB maintains the ionic homeostasis for 
neuronal functions, regulates the nutrient transport to the CNS and the level of toxic 
metabolites, provides protection from xenobiotics and represents a communication 
interface between the periphery and the brain (Campos-Bedolla et al., 2014). The estimated 
length of human brain capillaries is 650 km and the surface area is 10 to 20 m
2
. This 
surface is the major entry route for therapeutic compounds to the CNS. Compared to other 
vascular endothelium, the passive penetration of hydrophilic molecules and ions across the 
para- and transcellular pathways of brain endothelial cells is very low. TJ proteins block 
the paracellular route, while the low level of non-specific transendothelial vesicular 
trafficking and the presence of efflux transporters at the luminal membranes of brain 
endothelial cells limit the penetration across cell membrane (Deli, 2011). The electrical 
resistance of brain microvessels is also high, more than 2000 Ω × cm2 indicating the 
limited ionic penetration through the BBB. Because the BBB restricts drug permeation, the 
treatment of many CNS diseases is still a challenge (Deli, 2011; Abbott, 2013). 
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1.2. Major mechanisms at biological barriers limiting the penetration of drugs 
Active agents can penetrate across epithelial and endothelial barriers by several 
pathways, including lipid-mediated diffusion, carrier or receptor mediated transport and 
paracellular passive diffusion (Laksitorini et al., 2014). The same mechanisms of 
biological barriers which provide protection also limit drug delivery. 
Efflux transporters limit the absorption and CNS delivery of lipophilic compounds, 
xenobiotics and a large number of drugs. Efflux pumps localize to the apical and/or 
basolateral side of polarized cell membranes of both the intestinal mucosa and the BBB 
(Fricker and Miller, 2004; Terasaki and Ohtsuki, 2005). Most efflux pumps belong to the 
ABC (ATP binding cassette) transporter family, like P-glycoprotein or multidrug 
resistance associated proteins, or to the SLC (solute carrier) family, like the organic anion-
transporting polypeptides.  
Barriers, including the endothelial cells of the BBB provide a metabolic barrier by 
expressing enzymes that modify endogenous and exogenous molecules (Cecchelli et al., 
2007; Deli, 2011). Peptide or neurotransmitter transport to the brain is restricted not only 
by this mechanism but also by the restricted paracellular route (Deli, 2011). Opioid 
peptides are potent analgesics with therapeutic potential in the treatment of acute and 
chronic pain but their efficacy is limited because of the short half-life time and low 
metabolic stability (Tömböly et al., 2002; Janecka et al., 2008). Opiorphin pentapeptide 
(QRFSR) is a human endogenous inhibitor of enkephalinases, which prevents the 
metabolism of opioid peptides (Rougeot et al., 2010; Javelot et al., 2010). Opiorphin is the 
only natural enkephalinase inhibitor which was characterized in human and has similar 
pain suppressive potency to morphine without adverse effects (Wisner et al., 2006). This 
peptide is able to increase the binding and affinity of endogenous opiates to μ-opioid 
receptors, thus the mechanism of opiorphin may provide a new therapeutic approach in 
pain management. The analgesic effect of opiorphin was verified in several in vitro and in 
vivo models (Wisner et al., 2006), but previously there were no data about their transfer 
through a BBB model. 
Lipophilic drugs possess high affinity for the lipid bilayer of the cell membrane, 
and their transcellular passive diffusion is considered as the major route of delivery, while 
the transcellular penetration of hydrophilic molecules is blocked. The permeability of 
drugs across paracellular pathway is modulated by TJs which seal the gaps between cells 
(Fig. 2; Johnson and Quay, 2005). TJs of barrier cells are complex structures (Fig. 3) 
composed of integral membrane proteins, linker proteins connecting membrane proteins to 
the actin cytoskeleton and signaling molecules regulating paracellular tightness and 
transport (Johnson and Quay, 2005; Van Itallie and Anderson, 2014). 
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Figure 2. Structure of tight junctions between epithelial cells (Johnson and Quay, 2005). 
 
Among the transmembrane TJ proteins occludin, tricellulin and the members of the 
claudin family have a prominent role in forming paracellular barriers (Krause et al., 2008). 
These TJ proteins share a tetraspan transmembrane topology (Fig. 2 and 3). Occludin 
which plays an important role in transport regulation is expressed at similar levels in 
different barrier-forming tissues, such as BBB forming brain endothelial cells or intestinal 
epithelial cells of GI (Haseloff et al., 2015). More than 20 members of the claudin family 
are expressed on epithelial and endothelial cells. The unique expression pattern of claudins 
determines the tissue-, charge- and size selectivity of the paracellular cleft. 
 
 
 
Figure 3. Tight and adherens junctional proteins between barrier forming cells (Johnson and Quay, 2005). 
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Claudin-1, -3, -4, -5, -8, -11, -14 and -19 contribute to the tightness of paracellular barriers, 
while claudin-7 is permeable for ions (Krause et al., 2008). Intestinal epithelial cells 
express claudin-1, -2, -3, -4, -7, -8, -12 and -15, but the level of their expression in various 
intestinal segments and their subcellular localization are different (Chiba et al., 2008). The 
presence of claudin-1, -3, -5, -12 and -18 were described in brain endothelial cells. 
Claudin-5 is the dominant claudin at the BBB which regulates the paracellular permeation 
of small molecules (Deli, 2009; Haseloff et al., 2015). Claudins can interact in a homo- and 
heterophilic manner in the plasma membrane of the same cell (cis-interaction) and between 
plasma membranes of opposing cells (trans-interaction) (Krause et al., 2009).  
Zonula occludens proteins (ZO-1, ZO-2) connect occludin and claudins to the actin 
cytoskeleton (Fig. 3) and dynamically modulate several signaling pathways and junctional 
permeability (Paris et al., 2008). Another important adaptor protein is “dual-function” β-
catenin, which stabilizes adherens junctions in the cell membrane, and acts as a key 
regulator of gene expression via binding to transcription factors (Reis and Liebner, 2013). 
 
 
Figure 4. Morphology of intercellular junctions between cultured intestinal epithelial and brain endothelial 
cells. D, desmosome; ER, endoplasmatic reticulum; ID, interdigitations; m, mitochondria; TJ, tight junctions; 
V, microvilli (Hellinger et al., 2012). 
 
Adherens junction proteins are also expressed in both epithelial and endothelial 
barriers, however, there are morphological and functional differences. In brain endothelial 
cells tight and adherens junctions are not separated morphologically (Fig. 4) and tight and 
adherens junctional proteins are intermingled (Vorbrodt et al., 2004). In epithelial barriers 
adherens junctions are situated in the apical junctional complex in basolateral direction 
from the TJs (Fig. 2-4) and play an important role in the localization of TJs (Johnson and 
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Quay, 2005). Adherens junction proteins, like E-cadherin in epithelial cells and VE-
cadherin in endothelial cells also participate in the regulation of paracellular permeability 
(Fig. 3; Deli, 2009). 
 
1.3. Strategies to enhance drug delivery across barriers 
There are three basic strategies to enhance the permeability of biological barriers 
and improve drug delivery: (i) using an alternative route of drug administration; (ii) 
modification of the pharmacon; (iii) modificaton of the function of the barrier including 
targeted opening of tight junctions (Deli, 2009). 
Alternative routes of drug administration such as the nasal pathway circumvent the 
BBB and allow pharmacons a direct transport route to the CNS (Illum, 2003). Previous 
results of our research group identified incomplete junctions between olfactory ensheating 
cells, which allowed the penetration of a marker molecule along the olfactory nerves to the 
CNS, as the anatomical basis of this alternative pathway (Wolburg et al., 2008). By 
exploiting this alternative route of delivery, our group described the brain penetration of a 
large marker molecule and a bioactive peptide after nasal administration in rats (Horvát et 
al., 2009; Sipos et al., 2011). Intranasal drug delivery can be an effective way to increase 
drug levels in the systemic circulation. We demonstrated that nasal administration of a 
meloxicam formulation which contained drug nanoparticles significantly increased plasma 
drug level compared to the oral administration route (Kürti et al., 2013). 
Pharmacons can be modified chemically to increase their cationic or lipophilic 
properties which are known to promote their crossing across barriers (Deli, 2011). 
Cyclodextrins, especially hydrophilic derivatives, not only solubilize lipophilic 
pharmacons, but also improve drug absorption by complex formation (Strickley, 2004; 
Loftsson et al., 2007). Experimental and clinical data suggest that cyclodextrins can be 
used to increase drug delivery to the brain (Vecsernyés et al., 2014). Prodrug design for 
brain delivery of small- and medium-sized neuropeptides is achieved by the chemical 
modification of the bioactive molecule, which is attached to a lipid vector, like a fatty acid, 
a glyceride or phospholipid (Prókai-Tátrai and Prókai, 2009). The pharmacologically 
inactive molecule, which penetrates through the barrier, will be released enzymatically 
only at the site of action (Table 1). This method was successful in the case of a lipophilic 
analog of valproate (DP-VPA) in a clinical trial for the treatment of epilepsy and 
depression (Deli, 2011). 
Ways to modify the two most important barrier properties, efflux transporters and 
TJs blocking drug penetration are actively investigated in pharmaceutical research. 
Inhibiting efflux pumps without systemic or CNS side-effects would be optimal for clinical 
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use to increase delivery of a wide variety of drugs, including antibiotics, antineoplastic 
agents and drugs to treat epilepsy and AIDS. While P-glycoprotein blockers, like 
cyclosporine A and verapamil are effective to enhance the penetration of drugs across 
barriers in experiments, the first- and second-generation P-glycoprotein modulators have 
failed in clinical trials due to toxic side effects (Szakács et al., 2009).  
 
Table 1. Restricted transport of different compounds through biological barriers and strategies to overcome. 
Barrier feature Blocked pathway Restricted transport Strategies to overcome 
Efflux transporters 
lipid-mediated transcellular 
diffusion 
lipophilic compounds 
efflux transporter 
inhibitors 
Enzymes 
carrier or receptor mediated 
transcellular transport 
bioactive pharmacons, 
peptide, proteins 
Prodrugs 
Lipid plasma 
membrane 
transcellular passive 
diffusion 
hydrophilic compounds absorption enhancers 
Tight junctions 
paracellular passive 
diffusion 
hydrophilic compounds, 
biopharmaceuticals 
opening the junctions 
 
Several approaches are used to open the paracellular route of barrier to increase the 
flux of hydrophilic molecules, especially larger biopharmaceuticals, including proteins, 
peptides or lipophilic efflux pump ligands (Deli, 2009; Deli, 2011). There are many well 
characterized and effective pharmaceutical excipients, like anionic and non-ionic 
surfactants and fatty acids which are widely used as solubilizing agents in oral, injectable 
and nasal formulations (Strickley, 2004). These excipients increase transcellular 
permeation and several studies described their absorption enhancer properties (Aungst, 
2012). In our previous work non-ionic surfactant sucrose esters were investigated on 
culture models of the intestinal and blood-brain barriers (Kiss et al., 2014). We 
demonstrated that sucrose esters can act on TJs and increase the paracellular permeability 
for ions, drugs and marker molecules (Kiss et al., 2014). 
Opening the TJs at the BBB to increase drug delivery for the treatment of 
neurological diseases, like brain tumors is especially challenging (Deli, 2011). Osmotic 
stress induced by intraarterial mannitol improves the delivery of cytostatic drugs to brain 
tumors and prolongs the survival of patients, but this technique is invasive and used only in 
few clinical centers (Doolittle et al., 2000). Short-chain alkylglycerols were also described 
to enhance the penetration of drugs across the BBB by opening TJs in rats (Erdlenbruch et 
al., 2003), and our group confirmed the direct, reversible action of these small lipid 
molecules on the paracellular pathway in cultured brain endothelial cells (Hülper et al., 
2013). We also demonstrated that tesmilifene, a tamoxifen analog increased the blood-
8 
 
tumor barrier permeability in rats and opened TJs in brain endothelial cells (Walter et al., 
2015). 
1.4. Tight junction modulator peptides 
Occludin was the first identified and cloned integral membrane TJ protein in the 
early 90s (Furuse et al., 1993), soon followed by different claudins (Krause et al., 2008). 
Knowledge of the amino acid sequence of these proteins and their (putative) secondary 
structure made it possible to design peptides as novel type of TJ modulators to open the 
paracellular barrier for drug delivery. A wide variety of modulator peptides were 
synthesized based on different junctional proteins and tested on barrier models in vivo and 
in vitro (Deli, 2009). Based on literature data we have selected for our study six different 
modulator peptides which act at different targets (Table 2). 
 
Table 2. Characteristics of the selected TJ modulator peptides. 
Peptide Target Mechanism Derived from Refrence 
ADT-6 E-cadherin EC1 domain analog designed to target EC1  Sinaga et al., 2002 
HAV-6 E-cadherin EC1 domain analog designed to target EC1 Kiptoo et al., 2010 
C-CPE Claudin-3, -4 interact with ECLs microbial toxin fragment Sonoda et al., 1999 
AT-1002 ZO-1 Zot receptor microbial toxin fragment Song et al., 2008 
7-mer 
(PN78) 
unknown unknown phage display Herman et al., 2007 
PN159 unknown unknown phage display Johnson and Quay, 2005 
 
Abbreviation: ZO-1, zonula occludens protein-1; EC1, first extracellular domain; ECL, extracellular loop. 
 
1.4.1. TJ modulator peptides acting on E-cadherin 
The first extracellular domain (EC-1) of E-cadherin mediates cell-cell adhesion 
(Fig. 5A). The bulge and groove regions of EC-1 are responsible for the trans interaction 
between two E-cadherins (Fig. 5B). Two hexameric peptides, ADT-6 and HAV-6 were 
designed based on these bulge and groove regions of EC-1 (Sinaga et al., 2002). These 
peptides interfere with the homophilic binding of E-cadherin, and time- and dose-
dependently increase the paracellular permeability in different epithelial cells (Kiptoo et 
al., 2011). Modulation of integrity of intercellular junctions by cadherin peptides depends 
on the epithelial cell type: Madin-Darby canine kidney (MDCK) cell monolayers were 
more sensitive for the effect of HAV-6 than Caco-2 cell monolayers (Makagiansar et al., 
2001). 
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Figure 5. (A) Simplified structure of E-cadherin, EC1 is shown in red. (B) The groove (SHAVSS, HAV-6 
peptide) and bulge (ADTPP, ADT-6 peptide) regions in the EC1-domain of E-cadherin (Sinaga et al., 2002). 
 
 
1.4.2. TJ modulator peptides derived from microbial toxins 
Several pathogenic bacteria and viruses increase barrier permeability because 
integral membrane TJ proteins can be receptors for their toxins. Microbial toxins or toxin 
fragments were therefore tested as modulators to enhance drug penetration through 
barriers. One example is the enterotoxin of the gut bacterium Clostridium perfringens 
(CPE), which binds to epithelial claudins (Sonoda et al., 2002) via its C-terminal 16-
residue long fragment (C-CPE) (Fig. 6). The non-toxic C-CPE fragment binds specifically 
to the second extracellular loop (ECL2) of claudin-3 and -4 and increases intestinal 
permeability in vivo and in vitro (Kondoh et al., 2006; Li et al., 2014). 
The enterotoxin of the intestinal pathogen Vibrio cholerae enhances the 
permeability of small intestinal mucosa acting on intercellular TJs through ZO linker 
proteins (Fasano in 1991). The active domain of cholera enterotoxin was named zonula 
occludens toxin (ZOT), and containes a hexamer peptide AT-1002. This active 
hexapeptide causes the redistribution of ZO-1 (Gopalakrishnan et al., 2009) and increases 
the permeability of epithelial, especially intestinal barriers in vitro and in vivo (Song et al., 
2008). 
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Figure 6. Modulation of TJs by peptides derived from microbial toxins C-CPE: C-terminal 16-residue long 
fragment of Clostridium perfringens enterotoxin. 
 
1.4.3. TJ modulator peptides identified by phage display 
Another approach to find novel TJ modulator peptides is to use phage display, a 
powerful method to select specific peptides for a given target. First a peptide library is 
prepared by cloning randomised oligonucleotides into the phage, than several rounds of 
specific binding-washing steps (panning) are followed by the elution of the phages bound 
to the target, amplification of the phages and DNA sequencing. Enriched peptides are 
synthesised and tested on models for biological activity (McCafferty and Schofield, 2015). 
The 7-mer (PN78) and PN159 peptides were identified by phage display on EGTA-treated 
cultured human bronchial epithelial cell layers (Johnson and Quay, 2005; Herman et al., 
2007). PN159 effectively increases the permeability of respiratory epithelium, in culture 
and animal experiments (Chen et al., 2006). 
 
 
Figure 7. Specific interaction between juntional proteins and peptides expressed by phages. PN159: tight 
junction modulator peptide. 
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Because these peptides were selected by phage display, their specific target proteins are 
unknown. They probably interact with the ECLs of integral membrane TJ protein(s) 
similarly to other modulator peptides. Based on the available data PN159 could be a 
potential permeability enhancer for drug therapy, but there are no published information 
about its targets, structure or long term safety. 
 
1.5. The use of culture barrier models for drug transport studies 
The prediction of permeability properties of new active agents or drug candidates 
across biological barriers is crucial in the early phase of drug development, especially for 
neuropharmacons (Vastag et al., 2009). There are many available methods, from in silico 
screening through non-cell-based and cell-based in vitro methods to animal studies and 
human clinical trials with different predictive values, speed and throughput (Veszelka et 
al., 2011). Cell culture-based barrier models have proved to be one of the most versatile 
tools in both basic research and permeability testing (Deli et al., 2005). There are several 
important characteristics that a culture barrier model for drug transport studies should 
fulfill including physiological barrier properties, easy use, reproducibility, costs and test 
capacity. In our studies we used two well characterized and widely used culture models of 
the intestinal and blood-brain barriers. 
Oral drug formulations are the most widespread in human therapy, therefore 
intestinal drug absorption is the most studied in pharmaceutical research. The human Caco-
2 cell line, which resembles the epithelium of small intestine both from structural and 
functional aspects (Hubatsch et al., 2007) is a routinely used culture model of intestinal 
drug penetration (Hellinger et al., 2010). The cells are polarized, grow in monolayer, 
possess microvilli, and form TJs between cells (Fig. 4). Caco-2 cells also express nutrient 
and efflux transporters, such as P-gp (Artursson et al., 2001; Hellinger et al., 2010).  
The treatment of neuronal diseases such as epilepsy, stroke, Alzheimer’s disease or 
brain tumors is still very difficult due to the low brain penetration of most novel drug 
candidates (Avdeef et al., 2015). Therefore, screening for BBB permeability has great 
importance in CNS drug discovery (Vastag et al., 2009; Veszelka et al., 2011). The 
primary cell based rat BBB triple co-culture model of our group has high complexity and 
good predictive value for drug penetration to brain (Nakagawa et al., 2009), and was 
favorably compared to surrogate models of the BBB (Hellinger et al., 2012). 
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2. AIMS 
While the triple co-culture BBB model was already tested for several types of 
marker molecules and drugs, it was previously not examined for the penetration of 
bioactive peptides. Therefore the first aim of this work was to study the transfer of an 
unlabeled neuropeptide, the analgesic opiorphin on our BBB culture model. 
Several types of TJ modulator peptides are described in the literature as discussed 
above, but detailed comparative studies were missing at the start of our work. For example, 
there are many observations on C-CPE or E-cadherin peptides but their efficacy was 
investigated on one type of barrier model only. No data were available on their barrier 
specificity or their efficacy compared to other types of TJ modulator peptides either. Thus 
we wanted to compare the six TJ modulator peptides shown in Table 2 that we selected 
based on their diversity of targets, mode of action and different sequence on two different 
barrier models. 
 
Our specific aims were the following: 
 
(i) Testing the effects of TJ modulator peptides on intestinal epithelial and blood-brain 
endothelial models for: 
cell viability 
barrier integrity 
cell morphology 
 
(ii) Comparing the efficacy, safety, reversibility and barrier specifity of TJ modulator 
peptides. 
 
(iii) Investigation of PN159 peptide for: 
dose dependence of efficacy 
long-term effect on cell viability 
reversibility of kinetic and morphological changes 
penetration enhancement for marker molecules and drugs 
 
(iv) Identification of the potential targets of PN159 TJ modulator peptide.  
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3. MATERIALS AND METHODS 
 
3.1. Materials 
All reagents were purchased from Sigma (Sigma-Aldrich, Ltd., Budapest, Hungary), 
unless otherwise indicated. 
 
3.2. Peptide synthesis 
Opiorphin (QRFSR), TJ modulator peptides and peptides with scrambled sequences 
(Table 3) were synthesized manually by our cooperation partners by using Fmoc as 
described in detail in Publications I and II in Appendix. In the case of opiorphin the side 
chain protecting groups used to building the peptide sequences were the following: trityl 
(Trt) for Gln, tert-butyl (t-Bu) for Ser and 2,2,5,7,8-pentamethylchroman (Pmc) for Arg. 
The couplings were performed by HOBt and DIC. The coupling efficiencies were 
monitored by the Kaiser test. The Fmoc groups were removed by a solution of 20% 
piperidine in dimethylformamide. The peptides were cleaved from the resin by incubating 
it with the mixture of TFA/TIS/H2O (48:1:1volume ratio) at room temperature for 3 hours, 
precipitated and washed with diethyl-ether and then lyophilized. The crude peptides were 
purified using a semi-preparative RP-HPLC column (opiorphin: Altima HP C18; tight 
junction peptides: Phenomenex Jupiter C18). Analysis and purity control was carried out 
on an analytical HPLC instrument. 
 
Table 3. Characteristics of the selected modulator peptides. 
Peptide Mw (Da) Amino acid sequence 
ADT-6  
640 
Ac-ADTPPV-NH2 
sc ADT-6 Ac-PTDVAP-NH2 
HAV-6 
628 
Ac-SHAVSS-NH2 
sc HAV-6 Ac-VSSSHA-NH2 
C-CPE 
2056 
SSYSGNYPYS ILFQKF-OH 
sc C-CPE FYSQYYGDNLSKSFIP-OH 
AT-1002 
797 
FCIGRL 
sc AT-1002 GLRIFC 
7-mer (PN78) 
1031 
FDFWITP 
sc 7-mer PWTFDIF 
PN159 
2871 
KLALKLALKALKAALKLA-amide 
sc PN159 AALKLAKALLKLLKALAK-amide 
 
Abbreviation: sc, scrambled sequence of peptides; Mw, molecular weight. 
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3.3. Cell cultures 
3.3.1. Human Caco-2 intestinal epithelial cell line 
Human Caco-2 intestinal epithelial cell line (Fig. 8) was purchased from ATCC 
(cat.no. HTB-37) and used until passage 60 for the experiments. Caco-2 cells were grown 
in DMEM/HAM’s F-12 culture medium with stable glutamine (Biochrom GmbH, Berlin, 
Germany) supplemented with 10 % fetal bovine serum (FBS; Pan-Biotech GmbH, 
Aidenbach, Germany) and 50 μg/ml gentamycin in a humidified incubator with 5 % CO2 at 
37°C. All plastic surfaces were coated with 0.05 % rat tail collagen in sterile distilled water 
before cell seeding. 
 
 
Figure 8. Phase contrast images of confluent cultures of Caco-2 and rat brain endothelial cells (BBB). 
Bar = 50 μm. 
 
3.3.2. Culture model of the blood-brain barrier 
Primary cultures of brain endothelial cells, glial cells, and pericytes, and the in vitro 
BBB model were prepared according to the method described in our previous study 
(Nakagawa et al., 2009). Brain endothelial cells (Fig. 8) were cultured in DMEM/F-12 
(Gibco, Life Technologies, Carlsbad, CA, USA), 15 % plasma-derived bovine serum (First 
Link, Wolverhampton, UK), 100 µg/ml heparin, 5 µg/ml insulin, 5 µg/ml transferrin, 
5 ng/ml sodium selenite, 1 ng/ml basic fibroblast growth factor (Roche, Basel, 
Switzerland) and 50 µg/ml gentamycin. During the first three days of culture the medium 
of brain endothelial cells contained 3 µg/ml puromycin to eliminate P-glycoprotein 
negative, contaminating cell types (Perrière et al., 2005). During the experiments brain 
endothelial cells were always seeded on surfaces coated with 100 µg/ml collagen type IV 
and 100 µg/ml fibronectin in sterile distilled water. Primary rat brain pericytes were 
isolated by the same method, except pericytes were plated onto uncoated Petri dishes 
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(Orange Scientific, Braine-l’Alleud, Belgium). Primary cultures of rat glial cells were 
prepared from one-day-old Wistar rats (Perrière et al., 2005) and passaged to 12-well 
dishes (Corning, Costar, New York, NY, USA) coated with 100 µg/ml collagen type IV in 
sterile distilled water and cultured for two weeks before using for the triple co-culture 
model. Pericytes and glial cells were cultured in DMEM/HAM’s F-12 supplemented with 
10 % FBS (Pan-Biotech GmbH) and 50 µg/ml gentamycin. For the triple co-culture model 
pericytes (P3) were passaged to the bottom side of 12-well tissue culture inserts (Transwell 
3460, polyester membrane, 0.4 µm pore size, Corning Costar) at a density of 1.5 × 104 
cells/cm
2
. Endothelial cells were seeded to the upper side of the membranes (8 × 104 
cells/cm
2
) and placed to 12-well plates containing glial cells. Both compartments received 
endothelial culture medium and the three types of cells were cultured together for four or 
five days (Nakagawa et al., 2009; Walter et al., 2015) When brain endothelial cell layers 
became confluent 550 nM hydrocortisone was added to tighten the junctions (Deli et al., 
2005). For experiments with Caco-2 cells passage numbers were close to each other. For 
the BBB model primary cultures were obtained from several isolations, but the barrier 
parameters were very similar in the assays. 
 
3.4. Peptide treatment concentrations and intervals 
The stock solutions (10 mM) were prepared freshly, ADT-6, HAV-6, C-CPE and 
AT-1002 peptides were dissolved in sterile distilled water, while 7-mer (PN78) and PN159 
peptides were dissolved in sterile DMSO. Treatment solutions were further diluted in 
Ringer-Hepes (150 mM NaCl, 6 mM NaHCO3, 5.2 mM KCl, 2.2 mM CaCl2, 0.2 mM 
MgCl2, 2.8 mM D-glucose, 5 mM Hepes; pH 7.4) or cell culture medium. For the 
comparative studies final concentrations of the peptides in treatment solutions were as 
follows: 2 mM for ADT-6, HAV-6 and AT-1002 peptides, 1 mM for C-CPE peptide, 
100 µM for 7-mer peptide and 10 µM for PN159 peptide. For additional experiments with 
PN159 peptide final concentrations in treatment solutions were as follows: 1, 3, 10, 30 and 
100 µM for cell viability assays; 1, 3, 10 and 30 µM for the barrier integrity assays and 
10 µM for the recovery measurements. Peptide concentrations were selected based on 
literature data
 
(Deli, 2009) and cell viability experiments. 
 
3.5. Cell viability studies 
Two methods were applied to determine the effects of TJ modulator peptides on 
cell viability: MTT dye conversion assay, and cell impedance measurement. 
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3.5.1. MTT dye conversion assay 
For the cell viability assays Caco-2 epithelial cells and rat brain endothelial cells 
were seeded to 96-well plates at the density of 6 × 103 cells/well (Orange Scientific) and 
cultured for 3-5 days. Confluent cultures were treated with peptides in phenol red free 
DMEM (Life Technologies, Gibco, Carlsbad, CA, USA) for 1 hour. In the case of PN159 
peptide the treatments were also 1-hour long at concentrations of 1, 3, 10, 30 and 100 μM. 
MTT tests were performed at three different time points: (i) immediately after the 1-hour 
long treatment and at one-day recovery for all six peptides, (ii) at one-week recovery for 
PN159. To determine 100 % toxicity cells were incubated with 1 mg/ml Triton X-100 
detergent. After treatment the medium was changed and 0.5 mg/ml MTT solution was 
added to the cells for 3 h in a CO2 incubator. The metabolic activity of cells is reflected by 
the conversion of the yellow 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) dye to purple formazan. Formazan crystals were dissolved in DMSO and the 
amount of converted dye was determined by measuring absorbance at 595 nm wavelength 
with a microplate reader (Fluostar Optima, BMG Labtechnologies, Ortenberg, Germany). 
Cell viability/metabolic activity was calculated as percentage of dye conversion by non-
treated cells. 
 
3.5.2. Impedance measurement 
Kinetics of epithelial and endothelial cell reaction to peptide treatment was 
monitored by impedance measurement at 10 kHz (RTCA-SP instrument, ACEA 
Biosciences, San Diego, CA, USA). Impedance measurement is label-free, real time, non-
invasive and correlates linearly with adherence, growth, number and viability of cells (Kiss 
et al., 2013; Kürti et al., 2012). For background measurements 50 μl cell culture medium 
was added to the wells, then cells were seeded at a density of 6 × 103 cells/well to coated 
96-well plates with integrated gold electrodes (E-plate 96, ACEA Biosciences). Cells were 
cultured for 5-7 days in CO2 incubator at 37°C and monitored every 10 minutes until the 
end of experiments. At the beginning of plateau phase of growth cells were treated with 
peptide solutions and the effects were followed for 24 hours. In the case of PN159 cells 
were also treated with peptide solutions at 1, 3, 10, 30 and 100 μM concentrations at the 
beginning of the plateau phase of growth and the effects were followed for 24 hours. To 
measure cell recovery PN159 solutions were changed to culture medium and the 
impedance was monitored for one week. Culture medium was changed every 2 days. 
Triton X-100 detergent (1 mg/ml) was used as reference compound inducing cell toxicity. 
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Cell index was defined as Rn-Rb at each time point of measurement, where Rn is the cell-
electrode impedance of the well when it contains cells and Rb is the background impedance 
of the well with the medium alone. 
 
3.6. Measurement of the paracellular barrier integrity 
3.6.1. Electrical resistance of cell layers 
Transepithelial or transendothelial electrical resistance (TEER) reflects the 
tightness of the intercellular junctions (Benson et al., 2013). TEER was measured by an 
EVOM volt-ohmmeter (World Precision Instruments, Sarasota, FL, USA) combined with 
STX-2 electrodes, and was expressed relative to the surface area of the monolayers as 
Ω × cm2. Resistance of cell-free inserts (130 Ω × cm2) was subtracted from the measured 
values. For the measurement of barrier integrity Caco-2 cells were seeded onto Transwell 
inserts (Fig. 9A) and cultured for three weeks (Hellinger et al., 2012; Kiss et al., 2014). 
The BBB model was used after 4-5 days of co-culture (Fig. 9B). For both models culture 
medium was changed and resistance was checked every second day. Barrier models were 
used for permeability experiments when high TEER values reflecting tight intercellular 
junctions were measured. 
 
3.6.2. Permeability studies 
For permeability experiment inserts were transferred to 12-well plates (Figs. 9C 
and 9D) containing 1.5 ml Ringer-Hepes buffer in the lower (basal/abluminal) 
compartments. In the upper (apical/luminal) compartments culture medium was replaced 
by 0.5 ml buffer containing peptide solutions for 1 hour. Permeability marker molecules 
albumin (10 mg/ml; Mw: 65 kDa) labeled with Evans blue (167.5 μg/ml) and fluorescein 
(10 μg/ml; Mw: 376 Da) were added 30 minutes later. The incubation with permeability 
markers in the presence of peptides lasted for 30 minutes. Treatment solutions from both 
compartments were collected and after a gentle wash were changed for culture medium. 
Cells were kept in CO2 incubator at 37°C for 24 hours then after the measurement of TEER 
the permeability experiments were repeated. 
To measure the transfer of opiorphin across the BBB model cell culture inserts 
were also transferred to 12-well plates containing 1.5 ml Ringer-Hepes solution in the 
lower or acceptor compartments. The peptide was dissolved in distilled water to yield a 
10 mM solution, which was further diluted in Ringer-Hepes buffer. In the upper or donor 
chambers culture medium was replaced by 0.5 ml Ringer-Hepes buffer containing 
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opiorphin at 10 μM concentration. To measure peptide flux from the upper to lower 
compartment (blood to brain direction) the inserts were transferred at 30 and 60 minutes to 
new wells containing Ringer-Hepes solution. Samples were collected after the experiments 
and the opiorphin levels were detected by mass spectrometry. 
 
 
Figure 9. (A) Human Caco-2 cell line and (B) primary rat brain cells were cultured on Transwell inserts for 
(C-D) permeability assays. 
 
The concentrations of the marker molecules of collected samples were determined 
by a fluorescence multi-well plate reader (Fluostar Optima; for fluorescein: excitation 
wavelength: 485 nm, emission wavelength: 535 nm; for Evans-blue labeled albumin 
excitation wavelength: 584 nm, emission wavelength: 680 nm). To test the reversibility of 
the peptide effect inserts with the cells were placed back to the culture plates containing 
medium after the permeability tests. Treatment solutions from the upper compartments 
were removed and after a gentle wash were changed for culture medium. Cells were kept 
in CO2 incubator at 37°C for 24 hours then after the measurement of TEER the 
permeability experiments were repeated. 
In permeability experiments with PN159 (10 μM) on Caco-2 cells fluorescein 
isothiocyanate (FITC)-labeled dextran marker molecules (Table 4) were used at 1 mM 
concentrations, and fluorescence intensities of collected samples were measured using a 
Fluorolog FL3-22 spectrofluorometer (Horiba Jobin Yvon, Paris, France) using 492 nm 
excitation wavelength, 515 nm emission wavelength, and 0.5 s integration time. Drugs 
were used at 10 μM concentrations and samples were measured by HPLC (Methods 3.12.). 
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Table 4. Molecular weight of the tested FITC-labeled dextrans and drugs. 
Markers Mw (Da) Property Drugs MW (Da) Property 
FD-4 4.4 hydrophilic atenolol 0.266 lipophilic 
FD-10 9.4 hydrophilic cimetidine 0.252 lipophilic 
FD-20 17.2 hydrophilic quinidine 0.324 hydrophilic 
FD-40 35.6 hydrophilic verapamil 0.4554 hydrophilic 
 
Abbreviation: FD, FITC-labeled dextran molecule; Mw, molecular weight. 
 
The apparent permeability coefficients (Papp) were calculated as described 
previously (Kiss et al., 2014; Kürti et al., 2012). Briefly, cleared volume was calculated 
from the concentration difference of the tracer in the lower/basal compartment (Δ[C]B) 
after 30 minutes and upper/apical compartments at 0 hour ([C]A), the volume of the 
lower/basal compartment (VB; 1.5 mL) and the surface area available for permeability (A; 
1.1 cm
2
) using this equation: 
 
  tCA
VC
L 

 AA(cm/s) Papp  
 
3.7. Immunohistochemistry 
Morphological changes in epithelial and endothelial barrier integrity were followed 
by immunostaining for TJ proteins occludin, claudin-1 and -5, adherens junction protein E-
cadherin and linker proteins β-catenin and ZO-1 after peptide treatments and one-day 
recovery. After treatments cells were washed with phosphate buffer (PBS), and fixed with 
1:1 mixture of ice cold acetone and methanol for 10 minutes at room temperature. After 
blocking with 3 % bovine serum albumin in PBS cells were incubated with primary 
antibodies rabbit anti-occludin, mouse anti-claudin-5 and anti-claudin-1, mouse anti-E-
cadherin, rabbit anti-ZO-1, and rabbit anti-β-catenin (Life Technologies, Carlsbad, CA, 
USA) overnight. Incubation with secondary antibodies Alexa Fluor-488-labeled anti-
mouse (Life Technologies, Invitrogen, USA) and Cy3-labeled anti-rabbit lasted for 1 hour. 
Hoechst 33342 was used to stain cell nuclei. After mounting the samples (Fluoromount-G; 
Southern Biotech, Birmingham, USA) staining was visualized by a Leica TCS SP5 
confocal laser scanning microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
 
3.8. Quantitative real-time PCR 
Gene expression analysis was performed as described recently by our group (Tóth 
et al., 2014). Confluent cultures were washed, scraped, collected and cell pellets were used 
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for total RNA isolation using RNAqueous-4PCR Kit (Life Technologies, Ambion, Austin, 
TX, USA). cDNA synthesis was performed by High Capacity cDNA Reverse 
Transcription Kit (Life Technologies). The expression of occludin and the selected claudin 
genes were analyzed by quantitative PCR using TaqMan Low Density Array 384-well 
microfluidic cards preloaded with inventoried TaqMan Gene Expression Assays 
(Appendix, Publication II, Supplementary material; Life Technologies, Applied 
Biosystems, Austin, TX, USA). Expression of all genes was normalized to the 18S rRNA 
as endogenous control, highly expressed in eukaryotic cells. Expression values of studied 
genes were determined by the correlation of normalized expression of genes calculated by 
2
-Ct
 formula to the lowest expression level which can be safely detected by this method. 
 
3.9. Microscale thermophoresis 
Association between PN159 peptide and claudins was measured with microscale 
thermophoresis (Jarabek-Willemsen et al., 2011). The claudins carried yellow fluorescence 
protein (Piontek et al., 2011) and the peptide was added in defined amounts as titration 
series (in PBS, 15 dilutions). After incubation (1 hour, 22 °C), samples were loaded into 
standard treated capillaries, and fluorescence was measured with Monolith™ NT.115 
(light-emitting diode power 50 %, infrared laser power 80 %, laser-on time 35 s). 
Evaluation was performed with NT Analysis software 1.2.229 (NanoTemper, Munich, 
Germany). Binding was characterized by dissociation constant (Kd). Determination was 
achieved using saturation-binding curves obtained at equilibrium (Dabrowski et al., 2015). 
 
3.10. Molecular modeling 
Protein structures were obtained by homology modeling using the MODELLER 
program package (Sali and Blundell, 1993). First, the structure of mouse claudin-15 was 
completed by homology modelling because its x-ray structure file is lacking the fragment 
of residues from 34 to 41 (Suzuki et al., 2014). Human claudins 1, 3, 4, 5 and 7 were 
homology modeled using the completed mouse claudin-15 as a template. The protein 
homology models were further relaxed by a short (400 ns) molecular dynamics simulation 
in which the proteins were embedded in a 95 by 95 Å POPC bilayer-water system 
containing 150 mM NaCl. Molecular dynamics simulations were performed by the 
program NAMD using the CHARMM27 molecular force field with CMAP correction 
(Phillips et al., 2005). The results were visualized by VMD v1.9.1 (Humphrey et al., 1996). 
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The docking studies were performed by the CABS docking server and the resulted C-alpha 
traces were reconstructed by MODELLER using the python script supplied by the server 
homepage (Kurcinski et al., 2015). 
 
3.11. Circular dichroism spectroscopy 
Far-UV circular dichroism (CD) spectra of PN159 peptide were recorded at 25 °C 
temperature on a J-810 spectropolarimeter (JASCO International Co. Ltd., Tokyo, Japan). 
The CD spectra were measured between 260 nm and 185 nm with an optical pathlength of 
1 mm, at a peptide concentration of 0.1 mg/ml in Milli-Q water diluted directly from 
powder. The bandwidth was 2 nm and data pitch 0.5 nm, the scan speed was set to 
100 nm/min and the integration time was 1 s. Ten spectra were accumulated and plotted. 
The data were analyzed by CDSSTR method on the Dichroweb server. To test the stability 
of the peptide structure the CD spectra were recorded between 25 
o
C and 95 
o
C 
temperature with a ramp rate of 5 
o
C/min on a JASCO J-810 spectropolarimeter by using a 
Peltier sample holder. The CD spectra were measured immediately between 260 and 
185 nm with an optical pathlength of 1 mm, the peptide concentration was 0.1 mg/ml in 
Milli-Q water. The bandwidth was 2 nm and data pitch 1 nm, the scan speed was set to 
100 nm/min and the integration time was 1 s, five spectra were accumulated and plotted. 
 
3.12. HPLC analytical procedures 
Analytical measurements were performed on a Merck-Hitachi LaChrom HPLC 
system equipped with an UV and a fluorescence detector (Merck, Darmstadt, Germany). 
All reagents were used of analytical reagent grade. Atenolol and verapamil were 
determined by using a Gemini C18 column (150 × 3 mm, 5 μm, 110 Å; Phenomenex Inc., 
Torrance, CA, USA) operated at 0.5 ml/minute flow rate, maintained at 35 °C. For atenolol 
measurements isocratic elution was applied with a mixture of 300 ml methanol, 400 ml 
100 mM ammonium acetate, 20 ml 10 % ammonium-hydroxide and 2 ml 0.1 M ethylene-
diaminetetraacetic acid. Mobile phase for verapamil consisted of 350 ml methanol with 
250 ml 20 mM ammonium acetate and 2 ml 10 % trifluoroacetic acid with isocratic 
elution, at 0.5 ml/minute flow rate. UV detection for atenolol was performed at 270 nm 
while for verapamil 230 nm wavelength was adjusted. The calibration curve was linear 
(r
2
 = 0.9999) over a range of 0.01–1.5 μM for atenolol. The calibration curve for verapamil 
also showed a good linearity within the examined concentration range of 0.01–1 μM 
(r
2
 = 0.9952). In both cases 10 μl sample was injected into the chromatographic system. 
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Samples at higher than 1 μM atenolol and verapamil concentrations were 10 × diluted with 
Ringer-Hepes solution.  
HPLC measurement of quinidine was performed using a YMC Pack Pro C18 
column (RS 150 × 2.1 mm, 5 μm, 80 Å; YMC America Inc., Allentown, PA, USA) 
equipped with a guard column operated at 0.2 ml/minute flow rate. The chromatographic 
column was maintained at 40 °C and 5 μl sample was injected onto the column. The 
elution of quinidine was performed with a buffer containing a mixture of 100 ml methanol, 
250 ml 0.1 % ammonium acetate, and 4 ml 10 % trifluoroacetic acid. Quinidine was 
quantified at 250/430 nm excitation/emission wavelengths. The calibration curve was 
linear over the quantitation range of 0.01–1 μM (r2 = 0.9984). 
HPLC measurement of cimetidine was performed using a Gemini NX column 
(150 × 4.6 mm, 3 µM) equipped with a guard column operated at 0.8 ml/minute flow rate. 
The column temperature was maintained at 40 °C and 20 μl sample was injected onto the 
chromatographic system. A buffer comprising of 15 % acetonitrile and 85 % 100 mM 
ammonium acetate was utilized for the isocratic elution of cimetidine. UV detection was 
set at 228 nm. The calibration curve was linear (r
2
 = 0.9999) over the range of 0.01-10 μM. 
 
3.13. Mass spectrometry 
LC-MS experiments were performed on a nanoAcquity UPLC (Waters) on-line 
coupled to an Orbitrap-Elite (Thermo Scientific) hybrid tandem mass spectrometer 
operated in the positive ion mode. Five µl of the samples containing opiorphin peptide was 
injected onto a trapping column (Waters Symmetry C18; 180µm × 20 mm, 5 µm particle 
size) and after washing with 1 % solvent B for 5 minutes was transferred onto the 
separating column (Dionex Acclaim PepMap;75 µm × 25 cm, 2 µm particle size, 100 Å 
pore size) developing a linear gradient of 1-35 % solvent B in 10 minutes using a flow rate 
of 200 nl/minute (solvent A: 0.1 % formic acid/water; solvent B: 0.1 % formic 
acid/acetonitrile). For MS experiments, mass range of m/z: 200-600 was monitored at 
resolution of 60000 using internal calibration to the background polysiloxane ion 
(m/z:445.120024). Relative quantity of opiorphin was estimated using the extracted ion 
chromatogram (XIC) of m/z: 347.1932 (±5 ppm) peak intensity corresponding to the 
doubly charged opiorphin peptide cation. 
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3.14. Electron microscopy 
Cells grown on culture inserts were treated with 10 μM PN159 peptide for 
30 minutes and fixed immediately after treatment or after a 1-day recovery. Cells were 
briefly washed with PBS and fixed with 3 % paraformaldehyde containing 0.5 % 
glutaraldehyde in cacodylate buffer (pH 7.4) for 30 minutes at 4 °C. After washing with 
the buffer several times, cells were postfixed in 1 % OsO4 for 30 minutes. Following a 
rinse with distilled water, the cells were block stained with 1 % uranyl acetate in 50 % 
ethanol for 30 minutes, dehydrated in graded ethanol and after the last step of dehydration 
inserts were placed in the 1:1 mixture of ethanol and Taab 812 (Taab; Aldermaston, Berks, 
UK) for 30 minutes at 30 °C. Finally, the membranes of the culture inserts with the cells 
were removed from their support and embedded in Taab 812. Polymerization was 
performed overnight at 60 °C. Ultrathin sections were cut perpendicularly for the 
membrane using a Leica EM UC6 ultramicrotome (Nussloch, Germany) and picked up on 
formvar-coated single-slot copper grids. The sections were examined using a Hitachi 7100 
transmission electron microscope (Hitachi Ltd., Tokyo, Japan) and a side-mounted Veleta 
CCD camera (Olympus Soft Imaging Solutions). Altogether 105 non-overlapping images 
from the 3 groups at the same magnification were analyzed for the presence or absence of 
tight junctions (control group n = 28; PN159 group n = 42; recovery group n = 35). 
 
3.15. Holographic phase contrast microscopy 
Caco-2 epithelial cells were treated with 10 μM PN159 peptide or culture medium 
in glass-bottom cell-culture dishes (MatTek Corp., Ashland, MA, USA) for 30 minutes. 
Digital holographic images were taken by the HoloMonitor M3 instrument (Phase 
Holographic Imaging AB, Phiab, Sweden) of control cells, peptide treated cells, and 
cultures after peptide treatment followed by a 1-day recovery. Cell morphological changes 
were analyzed by the Holostudio 2.4 software (Phase Holographic Imaging AB, Phiab, 
Sweden). 
 
3.16. Statistical analysis 
For statistical analysis GraphPad Prism 5.0 software (GraphPad Software Inc., San 
Diego, USA) was used. All data presented are means ± SD. Values were compared using 
analysis of variance followed by Dunnett’s test and t-test. Changes were considered 
statistically significant at p < 0.05. All measurements were repeated three times, the 
number of parallel samples was minimum three. 
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4. RESULTS 
4.1. Opiorphin penetration across a BBB culture model 
MS/MS characterization of the synthetic opiorphin peptide was performed using 
both collision induced dissociation and higher energy collisional activation. The observed 
m/z value of the protonated peptide ions and fragmentation pattern were in good agreement 
with those expected for the QRFSR sequence (Fig. 10A). Signal intensities in the receiver 
compartment samples were 1.5 × 108 as opposed to 1-2 × 106 in the donor compartment 
samples. The relative quantity of opiorphin which penetrated through the BBB model was 
calculated to be 2.91 ± 1.13 % based on the area under curve of the doubly charged 
opiorphin peptide ion m/z 347.1932. As a comparison, 0.41 ± 0.03 % of fluorescein and 
0.03 ± 0.01 % of albumin crossed the brain endothelial cell layers in parallel inserts from 
the same cell isolation under identical assay conditions.  
The clearance of opiorphin is shown on Fig. 10B. Papp of opiorphin was 
0.53 ± 1.36 × 10-6 cm/s (n = 4). In parallel inserts from the same cell isolation under 
identical assay conditions the Papp of fluorescein was 1.03 ± 0.09 × 10
-6
 cm/s (n=4) and that 
of albumin 0.07 ± 0.04 × 10-6 cm/s (n = 4). 
 
 
Figure 10. (A) Extracted ion chromatograms of m/z: 347.1932 ± 5 ppm corresponding to the doubly charged 
peptide ion of opiorphin. Upper panel: sample from the receiver compartment (“brain side”) after 30 minutes 
incubation, middle panel: sample from the receiver compartment after 60 minutes incubation, bottom panel: 
sample from the donor compartment (“blood side”) after 60 minutes incubation. Peak labels denote retention 
time and m/z value. (n = 4). (B) Clearance of opiorphin across the BBB model at 30 and 60 minutes (mean ± 
SD, n = 4).  
 
We have also observed rapid conversion of N-terminal glutamine into pyroglutamic 
acid both in 0.1 % formic acid and in Ringer-Hepes buffer used for BBB penetration 
experiments. We monitored the pyroglutamic acid containing peptide using its calculated 
molecular mass (monoisotopic Mw: 675.3453 yielding a doubly charged protonated 
peptide ion m/z:338.6799 (z = 2)).  
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4.2. Effect of TJ modulator peptides on cell viability 
Based on the colorimetric endpoint dye conversion MTT assay treatments with 
peptides for one hour did not cause significant change in the metabolic activity of Caco-2 
epithelial (Fig. 11A) or brain endothelial cells (Fig. 11B). Impedance measurement, a 
sensitive method to detect cellular effects revealed no decrease for a 1-hour treatment in 
Caco-2 cells (Fig. 11C). Brain endothelial cells were more sensitive; ADT-6, HAV-6 and 
AT-1002 peptides caused 15-20 % decrease in cell layer impedance after 1-hour treatment. 
As a comparison Triton X-100 caused 100 % toxicity in both assays (Fig. 11). 
 
 
 
Figure 11. Cell viability assays after 1 hour treatment with TJ modulator peptides. Peptide concentrations 
were the following: 2 mM for ADT-6, HAV-6 and AT-1002, 1 mM for C-CPE, 100 μM for 7-mer, and 
10 μM for PN159. (A) The toxicity of peptides on Caco-2 intestinal epithelial cells and (B) brain endothelial 
cells were measured by MTT dye conversion assay. The effect of peptides on the impedance of (C) epithelial 
and (D) brain endothelial cell layers are shown as cell index. The MTT and cell index are given as percent of 
control (100 % viability). Values are presented as means ± SD, n = 3-8. Statistical analysis: ANOVA 
followed by Dunnett’s test, p < 0.05 as compared with the control groups. 
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Long-term effect of peptides on epithelial and endothelial barriers was also 
determined (Fig. 12). In Caco-2 layers no change was seen in impedance except for a 
temporary increase after PN159 peptide treatment. In brain endothelial cells only AT-1002 
and C-CPE peptides decreased significantly the cell index after 24 hours. 
 
 
Figure 12. Kinetics of peptide effects on the impedance of (A) epithelial and (B) brain endothelial cell 
layers. Values are presented as means ± SD, n = 3-8. Statistical analysis: ANOVA followed by Dunnett’s 
test; p < 0.05, significant differences in peptide-treated groups at 24 hours as compared with control groups. 
 
The effects of peptides with scrambled sequences (Table 3) were tested on 
epithelial cells at the same concentrations, as negative controls. Peptides did not cause 
significant decrease in the cell index until 24 hours (Fig. 13). 
 
 
Figure 13. Effects of 24-hour treatment with scrambled peptides on Caco-2 epithelial cell viability. Data are 
shown as cell index in percentage of control group. Data are presented as means ± SD, n = 3-6. Statistical 
analysis: ANOVA followed by Dunett’s test. Statistically significant differences are p < 0.05, compared with 
control group.  
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4.3. Effect of TJ modulator peptides on barrier integrity 
4.3.1. Effect of modulator peptides on electrical resistance 
All six peptides significantly decreased the TEER of Caco-2 layers after 1-hour 
treatment (Fig. 14A). Treatments with ADT-6, C-CPE and PN159 reduced the resistance 
of cell layers by more than 50 %, while 7-mer, HAV-6 and AT-1002 caused a 30-45 % 
drop as compared to control (1309 ± 97 Ω × cm2). The resistance of brain endothelial 
monolayers was also decreased by the peptides, except C-CPE peptide, which had no 
significant effect (Fig. 14B). The TJ modulator peptides caused less than 50 % reduction of 
TEER compared to control (314 ± 48 Ω × cm2). PN159 peptide was the most effective on 
both models (Fig. 14). Barrier integrity was recovered in both models in all treatment 
groups after 24 hours. 
 
 
Figure 14. Effects of modulator peptides on the resistance of Caco-2 epithelial (A) and brain endothelial (B) 
cell layers. Empty columns represent the effect of 1-hour peptide treatment and striped columns show 
resistance after 24-hour recovery. Data are presented as means ± SD, n = 3-6. Statistical analysis: ANOVA 
followed by Dunett’s test. Statistically significant differences are: *, p < 0.05, compared to control group 
(Caco-2: 1309 ± 97 Ω × cm2; BBB: 314 ± 48 Ω × cm2); #, p < 0.05 compared to control group value 24 hours 
later (Caco-2: 1338 ± 53 Ω × cm2; BBB: 350 ± 60 Ω × cm2). 
 
 
4.3.2. Effect of modulator peptides on permeability of cell layers 
The modulator peptides increased the permeability of Caco-2 layers for fluorescein 
and albumin markers (Figs. 15A and 15B). ADT-6, HAV-6 and especially PN159 peptides 
were the most effective. PN159 peptide increased the epithelial permeability for 
fluorescein more than 200-fold and for albumin around 30-fold. The 7-mer peptide had no 
effect on fluorescein flux, but increased the permeability of albumin. On the BBB model 
AT-1002, 7-mer and PN159 peptides significantly enhanced the permeability of both 
markers (Figs. 15C and 15D). AT-1002 and 7-mer peptides increased the flux of markers 
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3.5-6-fold, while PN159 peptide showed the highest effect with about 10-fold increase. In 
the BBB model E-cadherin peptides had a small effect on fluorescein, but not on albumin 
penetration, while C-CPE had no effect. Permeability assays were repeated after 24-hour 
recovery and the TJ modulating effect of the peptides were reversible on both Caco-2 and 
BBB models. 
 
 
 
Figure 15. Evaluation of barrier integrity on Caco-2 epithelial (A and B) and brain endothelial cell layers (C 
and D). Permeability (A, C) for fluorescein and (B, D) for albumin after 1-hour treatment with modulator 
peptides and after 24-hour recovery. Empty columns represent the effect of 1-hour peptide treatment and 
striped columns show permeability after 24-hour recovery. Values of apparent permeability coefficients 
(Papp) in the respective control groups were: (A) fluorescein Papp in Caco-2: 0.20 ± 0.02 × 10
-6 
cm/s, and 
0.30 ± 0.02 × 10-6 cm/s; (B) albumin Papp in Caco-2: 0.26 ± 0.01 × 10
-6
 cm/s and 0.27 ± 0.01×10-6 cm/s; (C) 
fluorescein Papp in BBB model: 3.10 ± 0.26 × 10
-6
 cm/s and 3.42 ± 0.62 × 10-6 cm/s; (D) albumin Papp in BBB 
model: 1.59 ± 0.2 × 10-6cm/s and 1.61 ± 0.57 × 10-6 cm/s. Data is expressed in the % of control groups. 
Values are presented as means ± SD, n = 3-6. Statistical analysis: ANOVA followed by Dunett’s test and t-
test. Statistically significant differences were detected after treatment with peptides (p < 0.05) as compared 
with the control group (*) and compared with each peptides (#) after recovery. 
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Scrambled peptides had no influence on intestinal barrier integrity. Neither 
fluorescein nor albumin permeability changed after 1-hour treatment (Fig. 16). 
 
 
Figure 16. Permeability of Caco-2 cell layers for (A) fluorescein and (B) albumin after 1-hour treatment with 
scrambled peptides in the same concentration as Figure 15. Values of apparent permeability coefficients 
(Papp) in the control groups were for fluorescein: 0.2 ± 0.06 × 10
-6
 cm/s; for albumin: 0.17 ± 0.02 × 10-6 cm/s. 
Data are presented as means ± SD, n = 3-6. Statistical analysis: ANOVA followed by Dunett’s test. 
Statistically significant differences are p < 0.05, compared with control group. 
 
4.4. Effect of TJ modulator peptides on the morphology of intercellular junctions 
In both culture models the cells were tightly apposed and all junctional proteins 
were localized at the intercellular connections forming pericellular belts in control groups 
(Figs. 17-18). The E-cadherin peptides had robust effects on junctions of Caco-2 cells, 
fragmentation of β-catenin and E-cadherin stainings at the cell border and redistribution of 
the immunostaining to the cytoplasm was observed (Fig. 17). Microbial toxin C-CPE 
peptide caused visible changes in ZO-1, β-catenin and occludin immunostaining, labeling 
at the cell borders markedly decreased. AT-1002 and 7-mer peptides had slight effect on 
these junctional proteins. ZO-1 immunolabeling was less changed for peptide treatments 
except PN-159. Epithelial junctional morphology was drastically changed by PN159, ZO-1 
and β-catenin proteins partially disappeared from cell borders. Occludin immunostaining in 
several cells became absent in cell contacts, enriched in the cytoplasm and showed spotty 
staining pattern. All peptides, except C-CPE, influenced junctional morphology at the BBB 
model (Fig. 18). E-cadherin peptides, AT-1002 and 7-mer peptides had similar effects on 
immunostaining of ZO-1, β-catenin and claudin-5 proteins, labeling was less sharp on cell 
borders, gaps and holes appeared between the cells. PN159 peptide caused the biggest 
change in immunostainings for all three proteins in brain endothelial cell junctions (Fig. 
18). A strong decrease of the staining at the cell border was accompanied by an increase in 
staining over cell bodies. The morphological changes caused by the peptides were 
reversible after 24-hour recovery in both models (Figs. 17-18). 
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Figure 17. Effects of TJ modulator peptides on junctional morphology of Caco-2 cells. Immunostaining for 
occludin and zonula occludens-1 (ZO-1) tight junction proteins, and β-catenin and E-cadherin adherens 
junction proteins after 1-hour peptide treatment and 24-hour recovery. Red color: immunostaining for ZO-1, 
β-catenin and occludin. Green color: immunostaining for E-cadherin. Blue color: staining of cell nuclei.  
Bar = 25 µm. 
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Figure 18. Effects of TJ modulator peptides on junctional morphology of brain endothelial cells. 
Immunostaining for claudin-5 and ZO-1 tight junction proteins, and β-catenin adherens junction protein after 
1-hour peptide treatment and 24-hour recovery. Red color: immunostaining for ZO-1 and β-catenin. Green 
color: immunostaining for claudin-5. Blue color: staining of cell nuclei. Bar = 25 µm. 
 
4.5. Gene expression of occludin and claudins 
Occludin mRNA was highly expressed in both models (Fig. 19). In Caco-2 cells the 
expression of claudin-1, -3, -4 and -7 genes were the highest, while claudin -5, -11, and -19 
were not expressed. In contrast, in brain endothelial cells claudin-5 mRNA was the most 
32 
 
abundant, similarly to isolated brain capillary data. High levels of claudin-11 and -15 and 
lower levels of claudin-1 and -3 mRNA were measured in our culture BBB model. No 
expression of genes of claudin-7, -8, -14, -16 was measured in the BBB model. Claudin-18 
was not found in the cultures. 
 
 
Figure 19. Gene expression level of occludin and selected claudins in Caco-2 epithelial and brain endothelial 
cells. 
 
4.6. Affinity measurements of peptides to claudin proteins 
High affinity binding of PN159 was detected by microscale thermophoresis to 
claudin-5-YFP (Kd:327 nM) and claudin-1-YFP (Kd:820 nM). Unspecific binding 
(Kd > 4000 nM) was measured for claudin-3-YFP and YFP (negative control) (Figs. 20A 
and 20B). 
 
 
 
Figure 20. (A) Affinity measurements of the peptide PN159 to full-length claudins and (B) binding curve for 
claudin-5-YFP. The association was measured by microscale thermophoresis. YFP, yellow fluorescent 
protein; Kd, dissociation constant. 
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4.7. Dose dependent effect of PN159 peptide on viability, barrier integrity and 
morphology of epithelial cells 
4.7.1. Effect of PN159 peptide on Caco-2 cell viability – MTT test 
As a follow-up work to the comparative study the most effective peptide, PN159 
was further examined for safety and efficacy on Caco-2 epithelial cells. The colorimetric 
endpoint dye conversion MTT assay reflects the metabolic activity and viability of cells. 
MTT test was performed at three different time points after 1-hour treatment with different 
PN159 peptide concentrations: (i) immediately after the 1-hour treatment, (ii) at one-day 
recovery and (iii) at one-week recovery (Fig. 21). Low concentrations of the peptide (1-
10 μM) did not decrease cell viability, while cell damage was found at higher 30 and 
100 μM concentrations. The cytotoxic effect of PN159 at 100 μM concentration was not 
reversible after one day or one week. 
 
Figure 21. MTT assay after 1-hour treatment with PN159 peptide followed by 1 hour, 1 day or 1 week 
recovery. The MTT values are given as percent of control (100 % viability). Values are presented as 
means ± SD, n = 3-8. Statistical analysis: ANOVA followed by Dunnett’s test, p < 0.05 as compared with the 
control groups. 
 
4.7.2. Effect of PN159 peptide on Caco-2 cell viability – impedance 
Kinetics of PN159 effects on Caco-2 cells were followed by real-time impedance 
measurements (Fig. 22). Only the two highest peptide concentrations decreased the cell 
impedance after 1-hour treatment indicating cell damage (Fig. 22A), similarly to the results 
of the MTT assay. Based on both tests PN159 peptide treatment for 1 hour was non-toxic 
at 10 μM and lower concentrations, reversible at 30 μM and toxic at the highest 100 μM 
concentration.  
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Similar results were obtained by impedance measurement on Caco-2 cells treated 
with PN159 for 1 day, except for 100  μM (Fig. 22B). Because of its toxicty, the 100 μM 
concentration was not used in further experiments. 
 
 
Figure 22. Impedance measurements after (A) 1-hour treatment and (B) one-day treatment followed by a 
recovery phase of 1 week. The effects of PN159 peptide on the impedance were shown as cell index. 
Values are presented as means ± SD, n = 3-8. Arrows indicate change of culture medium. 
 
4.7.3. Effect of PN159 peptide on electrical resistance and permeability of Caco-2 cells 
All tested concentrations of PN159 peptide significantly decreased the resistance of 
epithelial cell layers (Fig. 23A). The two highest 10 and 30 μM concentrations opened the 
paracellular barrier the most causing 80-90 % decrease in TEER. In concordance, these 
two highest concentrations of PN159 showed the most effective permeability enhancer 
activity for both fluorescein and albumin (Fig. 23B). 
 
 
Figure 23. (A) Evaluation of barrier integrity on Caco-2 cell layers by measurement of transepithelial 
electrical resistance (TEER). (B) Caco-2 cell layer permeability for fluorescein and albumin marker 
molecules (Papp A-B 10
-6
 cm/s). Values are presented as means ± SD, n = 3-8. Statistical analysis: 
ANOVA followed by Dunnett’s test, p < 0.05 as compared with the control groups. 
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4.7.4. Effect of PN159 peptide on junctional staining of Caco-2 cells 
The concentration-dependent effects of the peptide on epithelial viability and 
barrier integrity were confirmed by immunostaining of junctional proteins claudin-1, ZO-1 
and β-catenin in Caco-2 cells (Fig. 24). Claudin-1 staining was the most sensitive to the 
peptide treatment, in concordance with the barrier integrity data. PN159 at concentrations 
of 10-100 μM caused a drastic change in epithelial junctional morphology.  
 
 
 
Figure 24. Effects of PN159 peptide on junctional morphology of Caco-2 cells. Immunostaining for claudin-
1, zonula occludens-1 (ZO-1) and β-catenin junctional proteins are shown in control conditions or after 1-
hour peptide treatment. Green color: immunostaining for ZO-1, β-catenin and claudin-1. Blue color: staining 
of cell nuclei. Bar = 25 µm. 
 
Because the peptide was safe for the cells but effectively opened the barrier at 
10 μM, this concentration was selected to reveal the kinetics of the reversibility of barrier 
opening, and to investigate its effects on drug penetration. 
 
4.8. Reversible effect of PN159 peptide on electrical resistance and ultrastructure of 
Caco-2 cell junctions 
The effect PN159 peptide was very rapid, the electrical resistance dropped already 
to 42 % of control value after 1 minute treatment (Fig. 25A), this decreasing tendency 
continued until the end of the 30-minute treatment (5 min: 16 %, 15 min: 2.7 %, 
30 min: 1.4 % of the control value). After the removal of the peptide the barrier function of 
Caco-2 cells was restored about 44 % of the control value at six hours and complete 
recovery could be observed at 20 hours. 
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The area of Caco-2 cells was analysed on holographic phase contrast microscopy 
images. PN159 treatment decreased the average cell area, while the area of cells in the 
control and 1-day recovery groups was similar (Fig. 25B). This result may reflect opening 
of junctions and concomitant decrease of cell surface and increase of the paracellular 
space. 
 
 
Figure 25. Reversible effect of PN159 peptide (10 μM, 30-minutes treatment, 24-hour recovery) on 
Caco-2 cells. (A) Kinetic analysis of transepithelial electrical resistance (TEER) after PN159 peptide 
treatment. (B) Cell area analysis of holographic phase contrast images in control, treated and 
recovery groups. (C) Transmission electron micrographs of cell-cell connections (arrowheads); 
bar = 400 nm. 
 
Intact TJs providing the morphological basis of barrier functions were visualized 
between Caco-2 epithelial cells in the control group by transmission electron microscopy, 
but no junctions were observed following treatment with PN159 peptide (Fig. 25C). The 
disappearance of intercellular TJs was reversible, because after 1-day recovery the 
ultrastructure of epithelial junctions became similar to control cells. 
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4.9. Effects of PN159 on the penetration of dextran marker molecules and drugs  
All these previous functional and morphological results pointed to the TJ opening 
effect of PN159 in Caco-2 cells which potentially can be exploited to increase drug 
penetration across the intestinal barrier. The permeability of Caco-2 monolayers was 
measured in the apical to basal (intestine to blood) direction for four water soluble dextran 
marker molecules of different size (Table 4) and four drugs, the hydrophilic atenolol and 
cimetidine, and lipophilic quinidine and verapamil (Table 5). All four drugs are substrates 
of active efflux transporters (Hellinger et al., 2010). 
 
Table 5. Apparent permeability coefficients of dextran marker molecules and drugs in the apical-
basal direction (Papp A-B, 10
-6
 cm/s) in control and PN159 treated cultures. The differences between 
control and treated groups were expressed in fold changes. 
 
  
Papp A-B (10
-6
 cm/s) ± SD Fold 
change control PN159  
m
a
rk
er
s FD-4 0.021 ± 0.001  4.2 ± 0.1 42 
FD-10 0.025 ± 0.01  4.8 ± 0.7 48 
FD-20 0.022 ± 0.002  3.5 ± 1.0 35 
FD-40 0.015 ± 0.003  6.0 ± 0.3 60 
d
ru
g
s 
atenolol 1.2 ± 0.3 36.3 ± 1.9 30.3 
cimetidine 0.9 ± 0.2 34.5 ± 4.5 38.3 
quinidine 45.0 ± 13.3 72.6 ± 2.4 1.6 
verapamil 46.2 ± 3.9 86.7 ± 18.8 1.9 
 
Abbreviation: FD, fluorescein isothiocyanate-labeled dextran. 
 
Apparent permeability coefficients of the large FD macromolecules were very low 
in control conditions but they were elevated by 35-60 fold following PN159 treatment. The 
highest increase was measured in the case of FD-40. The permeability of atenolol and 
cimetidine was the lowest from the tested molecules, while the highest penetration was 
measured for quinidine and verapamil on Caco-2 cells. PN159 treatment caused more than 
30 fold change for atenolol and cimetidine which penetrate slowly across the cells layers. 
In contrast, the peptide increased about 2 fold the permeability of the intestinal culture 
model for the lipophilic quinidine and verapamil. 
 
4.10. Characterization of the secondary structure of PN159 
According to the obtained CD spectra the secondary structure of PN159 peptide 
contains 11 % α-helix, 31 % β-sheet, 24 % turns and 34 % unordered structure (Fig. 26A). 
This secondary structure of PN159 peptide was relatively stable between 25 and 95 °C 
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(Fig. 26B). At 95 °C the β-sheet content decreased from 31 % to 24 %, the amount of turns 
did not change, while a slight increase was measured in the content of α-helix (from 11 % 
to 14 %) and unordered structure (from 34 % to 37 %). 
 
 
Figure 26. (A) Circular dichroism (CD) spectroscopy of PN159 peptide at 25 °C. (B) Heat stability 
measurement of the peptide structure. 
 
 
4.11. Structure and interaction of claudin-1, -4, -5 and -7 with PN159 
As shown on Fig. 19 the expression of claudin-5 is the highest in brain endothelial 
cells, while in Caco-2 intestinal epithelial cells claudin-1, -4 and -7 are the most abundant 
claudin subtypes which can be considered as potential targets of the barrier opening effects 
PN159. Claudin protein structures were obtained by homology modelling using the 
MODELLER program package (Fig. 27A; for the homology model of claudin-3 see the 
Supplementary information of Publication II in the Appendix). 
Docking of PN159 peptide to full length homology modelled human claudin 
monomers -1, -4, -5 and -7 was performed on the CABS server. Favorable docking poses 
located around ECL1 and ECL2 were seeked by both energetic and geometric 
considerations and analysed in all docking trajectories. Docking energies ("total energy") 
were decomposed to "ligand energy", "interaction energy" and "receptor energy" parts 
(Table 6). Correct docking poses were expected to have low values not only for the total 
energies, but as low as possible for all energy components simultaneously. Thus, the 
"ligand energy", "interaction energy" and "total energy" values were investigated. Based 
on the modeling, energetically highly favorable interactions were found between PN159 
and the ECLs of claudin-1, -4, -5 and -7, but not that of claudin-3 (Table 6). Docked poses 
of PN159 with ECLs of claudin-1, -4, -5 and -7 are shown on Fig. 27B. 
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Figure 27. (A) Modelling human claudin proteins (claudin-1, -4, -5 -7). (B) Docking of PN159 peptide to 
claudin proteins. Interacting residues are shown as sticks. Orange color: PN159 peptide; Yellow color: β-
strands; purple color: α-helices of claudins. 
 
Comparing the docking energy values of PN159 to claudins the following rank 
order in the strength of interaction can be established: claudin-3 < claudin-1 < claudin-4 < 
claudin-5 < claudin-7. The energy values from modeling (Table 6) correlate well with the 
rank order of the binding of PN159 to claudin-1, -3 and -5 (Fig. 20A). 
 
Table 6. Docking energy components of PN159 to selected human claudin monomers 
  Claudin-1 Claudin-3 Claudin-4 Claudin-5 Claudin-7 
Elig -34 -17 -61 -100 -32 
Eint -63 -59 -79 -76 -186 
Etot -1228 -1163 -1229 -1439 -1798 
 
Abbreviation: Etot: total energy; Elig: ligand energy; Eint: interaction energy 
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The amino acid sequence of ECL1 and ECL2 of the four claudins wich showed 
interaction with the TJ modulator peptide were compared and the most important amino 
acids which interact with PN159 were identified (Fig. 28). Four residues in ECL1, the 
polar Q44 and S/N/D53, the hydrophobic V55 and L71, and in ECL2 the polar N/Q156 
participate in major interactions with the peptide. 
 
 
 
Figure 28. Amino acid sequence of ECL1 and ECL2 of human claudin monomers 1, 4, 5 and 7. Conserved 
amino acids are indicated in the boxes. The amino acids which interact with PN159 according to docking 
studies are marked by yellow and light blue. Blue color indicates interacting amino acids shown on Fig. 27. 
ECL: extracellular loop. 
 
Q44 and V55 residues of claudin-1 and -7 form a binding pocket for L11 of the 
peptide, while the same two residues of claudin-4 bind L6 and K9 (Fig. 27-29). The polar 
S/N/D53 and L71 of claudin-4, -5 and -7 interact with K5, while the same amino acids of 
claudin-1 bind K12. The N/Q156 amino acid of ECL2 of all four claudins interacts with 
lysines: in the case of claudin-1 L17, claudin-4 L2, claudin-5 L4 and L6, claudin-7 L6, L8, 
L15, L17.  
 
 
 
Figure 29. Interaction between PN159 peptide and human claudin monomers 1, 4, 5 and 7. Amino acids of 
PN159 peptide which interact with the claudins according to docking studies are shown in yellow color. 
 
Based on the docking results, lysines, especially K1 and K5 and leucins L6 and L17 
of PN159 interact with all four claudins examined (Fig. 29). 
After docking of the peptide disappearance of β-strands in ECLs of claudins was 
observed (Fig. 27), which seems to be correlated with the strength of interaction (Table 6). 
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5. DISCUSSION 
TJ proteins between epithelial and endothelial cells form a physical barrier and 
restrict the free passage of molecules, among them many active ingredients, through the 
paracellular cleft. The presence of several enzymes creates a metabolic barrier and 
intensifies the limited penetration of drugs, especially peptide or proteins. Due to these 
properties drug penetration across biological barriers is limited and new strategies for 
improving the permability are needed. Therefore investigation of biopharmacon transfer 
across barriers is an important field in the pharmaceutical research. One of the strategies to 
increase drug penetration is the targeted opening of TJ proteins. In the present PhD work 
we compared for the first time the effects of six selected modulator peptides acting on 
different targets on cultured intestinal and blood-brain barrier models.  
 
5.1. Transfer of opiorphin across a culture BBB model 
We measured for the first time the transfer of the biopharmacon opiorphin across a 
BBB culture model. Instead of radiolabeling we used the native form of the peptide and a 
sensitive method, LC-MS, to detect opiorphin. Our data indicate that opiorphin crosses the 
BBB in vitro in the absence of plasma factors at a slow rate, which is lower than that of the 
paracellular marker fluorescein but higher than that of the passive transcellular marker 
albumin. At the same time the extent of penetration was significant, ~ 3 % in contrast to 
the low amount of the paracellular markers. As a comparison, numerous endogenous 
peptides or regulatory proteins have < 0.1 %/g uptake in brain and are still effective in the 
CNS after peripheral administration (Zlokovic et al., 1989; Banks et al., 1996). 
Among the opiates, the centrally active morphine has an uptake of only < 0.02 %/g 
brain (Advokat et al., 1991). The amount of opiorphin transferred across the BBB culture 
model indicates that a specific transport mechanism, a peptide transport system or 
receptor-mediated transcytosis, may be involved in its transfer. Six transport systems 
(PTS1-6) have been identified for peptides at the BBB, which transport enkephalins, 
arginine vasopressin, or pituitary adenylate cyclase-activating polypeptides, among others 
(Banks, 2015). The peptide/histidine transporter 2 (PHT2, SLC15a3) was described at the 
BBB carrying di- and tripeptides, whereas larger peptides or proteins like insulin or 
transferrin cross the BBB by receptor-mediated transcytosis (Campos-Bedolla et al., 2014). 
To reveal if carriers or transporters participate in opiorphin transfer, further experiments 
are needed. The relative quantity of opiorphin penetration through the BBB culture model 
is obviously more elevated than values obtained with iv-administered labeled opioid 
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peptides (Banks and Kastin, 1996). A possible explanation for this difference is that in our 
culture system no serum factors were present during the experiments, which is a limitation 
of the model. Peptidases are active in blood and rapidly cleave the native opiorphin 
peptide, which has a metabolic half-life of 6 min in human plasma; therefore, enzyme 
activity limits the transfer of opiorphin to the CNS in vivo (Wisner et al, 2006; Rougeot, 
2009). In vivo data suggest that even in the presence of serum peptidases opiorphin can 
cross the BBB in sufficient amounts to raise the concentration of endogenous opioid 
ligands by inhibiting enkephalinases; thus, it can be appropriate for producing central 
effects. Our results indicate that opiorphin crosses cultured brain endothelial cells. These 
data are in agreement with observations that opiorphin potentiates enkephalin mediated 
antinociception and exerts antidepressant-like effects. We suggest that opiorphin may have 
a potential for further development as a centrally acting novel drug for the treatment of 
pain or depression. 
 
5.2. Comparative study on TJ modulator peptides 
5.2.1. Peptides acting on E-cadherin  
Peptides HAV-6 designed for the bulge and ADT-6 designed for the groove regions 
of the EC1 domain of E-cadherin increased the permeability for marker molecules and 
decreased the TEER on Caco-2 intestinal cell layers. Our results are similar to those 
described on MDCK and Caco-2 epithelial cells (Sinaga et al., 2002; Kiptoo et al., 2011). 
We verified that the TJ modulator effect is reversible for both peptides. Full recovery of 
the barrier properties was also proved by immunostaining. Both peptides decreased TEER 
and induced reversible changes in immunostaining on the BBB model, but only ADT-6 
induced an increase in paracellular permeability for the small marker. In contrast to 
epithelial cells, ADT-6 did not change the flux of albumin and HAV-6 had no effect on the 
permeability of markers in cultured endothelial cells (Table 9). A possible explanation for 
the different action of the peptides on the two culture models could be that E-cadherin, 
specific for epithelial cells contain the HAV motif, a classical cadherin binding motif in the 
EC1 domains of type I subfamily members, but vascular endothelial VE-cadherin 
expressed in brain endothelial cells (Bazzoni and Dejana, 2004), a member of the classical 
type II subfamily, lacks this motif (Vestweber, 2008). 
 
  
43 
 
5.2.2. Peptides mimicking microbial toxins 
AT-1002 peptide acting on ZO-1 cytoplasmic TJ linker protein decreased resistance 
on both models and increased permeability particularly in the case of BBB, which is a new 
observation. Our results are in agreement with previous studies showing that this peptide 
increases the permeability of epithelial barriers (Song et al., 2008). In the present work 
AT-1002 was examined in lower concentration and with shorter incubation time than in 
previous studies (Song et al., 2008) because brain endothelial cells seemed to be more 
sensitive to the peptide effect than epithelial cells based on the impedance measurements. 
AT-1002 peptide treatment caused visible changes in immunostaining for all the junctional 
proteins examined including ZO-1 in both models indicating a marked effect on 
paracellular junctions. Importantly, these changes were reversible on both cell types.  
We observed that C-CPE peptide significantly decreased transepithelial resistance 
and increased the permeability of Caco-2 cell layers for marker molecules in agreement 
with literature data. The effects on Caco-2 cells were reversible, similarly to data obtained 
on MDCK kidney epithelial cells (Sonoda et al., 1999). In contrast to Caco-2 cells C-CPE, 
which was tested on the BBB model for the first time, did not act on brain endothelial 
cells. This clostridium toxin peptide fragment increases intestinal permeability mainly 
through claudin-3 and -4, but it cannot bind to claudin-1 and -5 due to its structure (Protze 
et al., 2015). Expression level of claudin-3 and -4 is high in epithelial, but low in brain 
endothelial cells explaining our results.  
 
5.2.3. Peptides discovered by phage display 
The 7-mer peptide decreased the transepithelial resistance without changing 
fluorescein penetration on Caco-2 cell layers in concordance with data on four different 
epithelial cell lines including Caco-2 cells (Herman et al., 2007). Interestingly, albumin 
flux was increased after peptide treatment indicating a mechanism other than the 
paracellular transport route, which is also supported by the visibly intact intercellular 
junctions. This peptide was not studied on endothelial cells previously; therefore our study 
was the first to show that the 7-mer peptide increases the permeability for small and large 
marker molecules on a co-culture BBB model. We revealed that endothelial cell junctions 
are more responsive to 7-mer peptide than Caco-2 cell junctions (Table 9). The other 
peptide selected by phage display, PN159 was the most effective modulator of junctional 
permeability in both models. This peptide was characterized as an effective modulator of 
airway epithelial TJs in vitro and in vivo (Johnson and Quay, 2005). The effect of PN159 
44 
 
was similar on bronchial epithelial cells than on Caco-2 cells (Johnson and Quay, 2005). 
However, until the present work there were no data on its effect on the BBB. This stable 
peptide with a low cytotoxicity profile and fully reversible action on different cell types 
has a potential for therapeutic application. Since PN159 peptide was originally discovered 
by phage technology on bronchial epithelial cell layers in which TJ proteins were made 
accessible by removal of calcium, its binding partner remained unknown so far. Our 
affinity measurements revealed that claudin-5 and claudin-1, but not claudin-3, can be 
among the potential targets of PN159.  
 
5.3. Comparison of the efficacy and barrier selectivity of the peptides 
All peptides induced reversible opening of junctions, but selectivity and differences 
in efficacy were observed. Comparing the efficacy of the peptides (Table 9) the following 
rank order can be established on Caco-2 cells: 7-mer < C-CPE < AT-1002 < HAV-6 < ADT-6 
< PN159. This order is different on the BBB model: C-CPE < HAV-6 < ADT-6 < 7-mer < AT-
1002 < PN159.  
 
Table 9. Comparison of the efficacy and barrier selectivity of the studied peptides. 
  ADT-6 HAV-6 C-CPE AT-1002 7-mer PN159 
Effective concentration 2 mM 2 mM 1 mM 2 mM 100 μM 10 μM 
Presence of target 
junctional protein 
Caco-2 + + + + ? + 
BBB - - - + ? + 
TEER reduction 
(%) 
Caco-2 52 40 68 61 35 96 
BBB 57 58 29 47 49 71 
Papp increase (fold 
change, SF/EBA) 
Caco-2 12/2 × 7/6 × 2.2/3.6 × 0.3/2 × 4.7/1.7 × 303/21.2  
BBB 1/0.7 × 0.6/0.7 × -/- 4.4/2.6 × 5.5/5 × 10/8.2 × 
Effect on barriers 
Caco-2 ++ ++ + -/+ + +++ 
BBB - - - + + ++ 
 
Abbreviation: Papp, apparent permeability coefficient; SF, sodium fluorescein; EBA, Evans blue labeled 
albumin. 
 
AT-1002 and 7-mer peptide increased the drug penetration on both models but 
showed more effective permeability enhancing effects on the BBB model, while the effects 
of C-CPE, ADT-6 and HAV-6 were selective to epithelial cells.The reason for these 
differences may be due to the differences between epithelial and brain endothelial cells. In 
our previous study major differences were demonstrated between the co-culture BBB and 
the Caco-2 models in their cytoarchitecture, TJ structure and immunostaining (Hellinger et 
al., 2012).   
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5.4. Further characterization of the structure, effects and interactions of PN159 TJ 
modulator peptide 
The most effective PN159 peptide was further studied to reveal its safety and 
efficacy, its secondary structure and the potential binding target(s). PN159 peptide exerted 
a concentration dependent effect on viability and barrier integrity of Caco-2 epithelial 
cells. The results of morphological examinations and the kinetic analysis of PN159 during 
treatment showed safe and reversible penetration enhancer effect in the micromolar range 
and did not cause cellular damage. In agreement with a previous study the permeability of 
the large marker molecules was very low in control conditions, the permeability of the 
small hydrophilic atenolol and cimetidine was higher and that of the small lipophilic 
quinidine and verapamil was the highest on Caco-2 cell layers (Hellinger et al., 2010). 
PN159 treatment successfully increased the permeability for marker molecules and 
especially for hydrophilic drugs. All these functional and morphological results points to 
the TJ opening effect of PN159 in Caco-2 cells which can potentially be exploited to 
increase drug penetration across the intestinal barrier. 
We present new data on the secondary structure of PN159, which contains 
predominantly random structure with β-sheet motives and shows thermostability. Our 
observation is in concordance with the high chemical stability of the peptide (Chen et al., 
2006). Furthermore we identified four potential targets of PN159 namely claudin-1, 4, -5 
and -7 by docking studies. These results suggest that PN159 peptide may open cell-cell 
junctions by acting on claudins, the most prominent family of integral membrane 
junctional proteins. C-CPE and C1C2 tight junction modulator peptides were described to 
target claudins. C-CPE is a fragment of Clostridium perfringens enterotoxin which directly 
binds claudin subtypes including claudin-4 and induces disintegration of tight junctions 
(Sonoda et al., 1999). The peptidomimetic C1C2 which contains the C-terminal half of 
ECL1 of claudin-1 predominantly binds to claudin-1, and -5 and opens the paracellular 
barrier in cultured cells (Staat et al., 2015). The secondary structure of C1C2 consists of β-
sheet stabilized by α-helix (Dabrowski et al., 2015), the claudin-binding domain of C-CPE 
is a nine-stranded β-sandwich (Veshnyakova et al., 2012), and PN159 also contains β-sheet 
beside the dominated random structure. This structural similarity between the three 
different but claudin-targeting peptides may be linked to the juntional modulator effect. 
Based on these results PN159 has a potential application of as a pharmaceutical excipient 
to improve drug delivery in oral formulations. 
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SUMMARY 
Epithelial and endothelial cells form the anatomical and functional basis of 
biological barriers. The penetration of drugs across these barriers is limited due to closed 
intercellular gaps by tight junction proteins, and metabolic enzymes expressed in cells. 
These important barrier properties which on one hand provide protection, on the other hand 
prevent the effective treatment of several diseases. The paracellular permeability is one of 
the most important determinants of drug delivery across biological barriers and enhancing 
the permeability of drugs, especially large biopharmaceuticals is a great challenge in 
pharmaceutical research. In the case of biopharmacon delivery beside tight junctions 
enzymes of the metabolic barrier represent the most limiting factor, particularly at the 
BBB. We demonstrated the transfer of opiorphin, a bioactive peptide across a well 
characterized and validated co-culture BBB model. Our data also support, that opiorphin 
may have a potential for further development as a centrally acting novel drug for the 
treatment of pain or depression. 
One of the strategies to increase the penetration of large hydrophilic compounds is 
opening the paracellular gate by targeting TJ proteins. We studied six tight junction 
modulator peptides, ADT-6, HAV-6, C-CPE, AT-1002, 7-mer PN-78, PN159, which act 
on different targets, and compared their effects on intestinal epithelial and brain endothelial 
barriers. All peptides induced reversible opening of tight junctions as confirmed by 
different methods, but selectivity and differences in efficacy were observed. The targets of 
C-CPE, ADT-6 and HAV-6 peptides are expressed on epithelial cells which resulted in 
selective effects on epithelial cells. AT-1002 and 7-mer peptides caused enhanced 
permeability on both models but they were less effective on the intestinal barrier model. 
The selectivity of these peptides offers a great potential for innovative targeted drug 
delivery. PN159 peptide was the most effective permeability enhancer on both models: a 
rapid and reversible effect was found in low, non-toxic concentrations without permanent 
morphological changes. Potential targets of PN159 peptide were identified as claudin-1, -4, 
-5 and -7 but not claudin-3 by affinity measurement and molecular modeling. The 
secondary structure and the high thermostability of PN159 were also revealed, which can 
be important for the development of new pharmaceutical formulations and drug delivery 
systems. The presented results indicate that these peptides can be effectively and 
selectively used as potential pharmaceutical excipients to improve drug delivery across 
biological barriers. 
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Opioid peptides are potent analgesics with therapeutic potential in the treatment of acute
and chronic pain. Their efficacy is limited by peptidases (enkephalinases). Opiorphin
pentapeptide (QRFSR) is the first characterized human endogenous inhibitor of enkepha-
linases. The peptide is able to increase the binding and affinity of endogenous opiates to
mu opioid receptors; thus, the mechanism of opiorphin may provide a new therapeutic
approach in pain management. The analgesic effect of opiorphin was proven in several
earlier published in vitro and in vivo studies. Our aim was to test the transfer of opiorphin
through a blood-brain barrier model for the first time. The flux of opiorphin was tested on
a blood-brain barrier culture model consisting of rat brain endothelial, glial and pericyte
cells. Brain endothelial cells in this triple co-culture model form tight monolayers char-
acterized by transendothelial electrical resistance measurement. Relative quantity of the
peptide was estimated by mass spectrometry. The transfer of opiorphin through the blood-
brain barrier model was estimated to be |3%, whereas the permeability coefficient was
0.53  1.36  106 cm/s (n5 4). We also observed rapid conversion of N-terminal gluta-
mine into pyroglutamic acid during the transfer experiments. Our results indicate that
opiorphin crosses cultured brain endothelial cells in the absence of serum factors in a sig-
nificant amount. This is in agreement with previous in vivo data showing potentiation of
enkephalin-mediated antinociception. We suggest that opiorphin may have a potential as
a centrally acting novel drug to treat pain.  2015 IMSS. Published by Elsevier Inc.
Key Words: Opiorphin, Peptidase inhibitor, Blood-brain barrier, Brain endothelial cell, Permeability,
LC-MS.
Introduction
Opioid analgesics are still one of the most effective drugs
against pain; however, their clinical usefulness is limited
by several side effects including physical dependence,
respiratory depression, gastrointestinal effects and toler-
ance (1). New opioid peptides could have therapeutic po-
tential for central nervous system (CNS) diseases, but
they have a short half-life and low metabolic stability
(2,3). Opiorphin (QRFSR) is an endogenous peptide that
inhibits Zn-dependent metallo-ecto-peptidases: neutral
endopeptidase (NEP EC3.4.21.11) and aminopeptidase
(AP-N EC3.4.11.2) (4). These enzymes metabolize
opioid peptides such as enkephalins and their derivatives
in vivo and in vitro (5). Opiorphin as an enkephalinase in-
hibitor exerts analgesic and antidepressive effects by the
protection of endogenous enkephalins released after
pain stimuli (6,7). Opiorphin is the only natural
enkephalinase-inhibitor characterized in humans and
has similar pain-suppressive potency to morphine but
without adverse effects (4,6). The efficacy of opiorphin
has been verified by in vitro methods and its analgesic ac-
tivity was also shown in different in vivo pain studies
(4,6,8). According to our previous in vitro maximal bind-
ing and affinity measurements, opiorphin is able to in-
crease the binding and affinity of endogenous opiates to
opioid receptors (9).
In this study we were interested in the opiorphin transfer
across the BBB. Opioid peptides have restricted penetration
to the CNS across the BBB (10,11). The transfer of opioid
peptides through the BBB was studied previously with
isotopically labeled peptides showing a penetration index
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!0.01% (12e14). Specific features of the BBB, mainly in-
terendothelial tight junctions and efflux transporters (15), as
well as peptidase activity in blood, brain microvessels and
brain tissue may be responsible for limiting the transfer of
these potential biotherapeutics from the blood to brain.
The aim of the study was to test the transfer of unlabeled
opiorphin across a well-characterized culture model of the
BBB. Mass spectrometry was used to detect the passage
of the peptide across the BBB in vitro.
Materials and Methods
Materials
All reagents used in the study were purchased from Sigma-
Hungary Ltd. (Budapest, Hungary) unless otherwise indi-
cated. Wistar rats were obtained from the animal facility
of the BRC. All animals were treated in strict accordance
with the NIH Guide for Care and Use of Laboratory Ani-
mals (NIH Publications No. 80e23) and as approved by
the local authority, Csongrad County Animal Health and
Food Control Station (Permit number: XVI./834/2012).
Peptide Synthesis
Opiorphin was synthesized manually using Fmoc (fluore-
nylmethyloxycarbonyl) solid phase synthesis on Na-
Fmoc-Arg(Pmc)-Wang resin. Na-Fmoc-protected amino
acids were used. The side chain protecting groups used to
build the peptide sequence were the following: trityl (Trt)
for Gln, tert-butyl (t-Bu) for Ser and 2,2,5,7,8-
pentamethylchroman (Pmc) for Arg. The couplings were
performed by 1-hydroxybenzotriazole (HOBt) and N,N0-
diisopropylcarbodiimide (DIC). The coupling efficiencies
were monitored by the Kaiser test. The Fmoc groups were
removed by a solution of 20% piperidine in dimethylforma-
mide. After assembly of the peptide sequence, a cocktail of
TFA/TIS/H2O (trifluoroacetic acid/triisopropylsilane/water,
95: 2.5: 2.5) was used to remove the side chain protecting
groups and to cleave the peptide from the resin. The resin
was filtered and the filtrate was cooled at 20C. After
precipitating with diethyl ether, the peptide was redissolved
in water and lyophilized. The crude peptide was purified us-
ing a semipreparative RP-HPLC column (Altima HP C18, 1
cm  25 cm, 5 mm particle size). The homogeneity of the
final peptide was determined by analytical RP-HPLC (Alti-
ma HP C18 0.46 cm  25 cm, 5 mm particle size) column,
retention time: 6.5 min. ESI-MS analysis confirmed the mo-
lecular mass of the peptide ([MþHþ]found: 693.5;
([MþHþ]theoretical: 693.4 Da).
Blood-Brain Barrier Model
Primary brain endothelial cells, astrocytes and pericytes
were isolated from 1-month-old Wistar rats. Cell isolation
and the preparation of the co-culture BBB model was per-
formed as previously described (16). Brain endothelial cells
and pericytes were seeded on the opposite surfaces of
collagen IV and fibronectin coated Costar Transwell poly-
carbonate inserts (12 mm diameter, 0.4 mm pore size; Corn-
ing, Corning, NY) and kept in co-culture with glial cells to
reach good barrier properties for the permeability measure-
ments (Figure 1A). The tightness of the model was checked
by transendothelial electrical resistance (TEER) measure-
ment using an EVOM resistance meter and STX-2 elec-
trodes (World Precision Instruments, USA). TEER of
coated, cell-free filters was subtracted from measured
TEER values of the BBB model. TEER of rat brain endo-
thelial cell layers was 593  47 U cm2 (mean  SD;
n 5 12) in agreement with our previous data (17).
Permeability Assay
To measure the transfer of opiorphin across the BBB model,
cell culture inserts were transferred to 12-well plates con-
taining 1.5 mL Ringer-Hepes solution (136 mM NaCl,
0.9 mM CaCl2, 0.5 mM MgCl2, 2.7 mM KCl, 1.5 mM
KH2PO4, 10 mM NaH2PO4, 25 mM glucose and 10 mM
Hepes, pH 7.4) in the lower or acceptor compartments.
The peptide was dissolved in distilled water to yield a
10-mM solution, which was further diluted in Ringer-
Hepes buffer. In the upper or donor chambers, culture me-
dium was replaced by 0.5 mL Ringer Hepes containing
Figure 1. Culture model of the blood-brain barrier (A). The model is a co-culture of three cells types, primary rat brain endothelial cells (EC), rat pericytes
(PC) and rat astrocytes (AC). In the permeability assay (B) culture inserts with EC and PC cells are used. Blue circles represent opiorphin, our test molecule.
The direction of the transfer from the donor to the acceptor compartment is indicated by an arrow. Clearance of opiorphin across the culture model (C)
(mean  SD, n 5 4). (A color figure can be found in the online version of this article.)
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opiorphin at 10 mM concentration or permeability markers
fluorescein (10 mg/mL; molecular weight: 376 Da) or bovine
serum albumin (1%, molecular weight: 65 kDa) bound to
Evans blue (165 mg/mL) (Figure 1B). To measure peptide
flux from the upper to lower compartment (blood to brain di-
rection) the inserts were transferred at 30 and 60 min to new
wells containing Ringer-Hepes solution. Opiorphin in sam-
ples from the donor and acceptor compartments (n5 4) were
detected by mass spectrometry. Evans blue-albumin content
of samples was measured at 584 nm excitation and 680 nm
emission wavelengths (Fluostar Optima, BMGLabtechnolo-
gies, Germany). Fluorescein concentrations were deter-
mined by the same instrument using 485 nm excitation and
520 nm emission wavelengths. Clearance and the apparent
permeability coefficient (Papp) were calculated as described
earlier (16) by the following equations:
Cleared volume ðmlÞ5CA VA
CD
where C is concentration of the peptide in the acceptor or
donor compartments and V is the volume of the acceptor
compartment (1.5 ml).
Pappðcm=sÞ5 D½CA VA
A ½CD Dt
where D[C]A is the concentration difference of the peptide
in the acceptor compartments after 1 h and CD is the con-
centration in the donor compartments at 0 h, and VA is
the volume of the acceptor compartment (1.5 mL), and A
is the surface area available for permeability (1.1 cm2).
The quantity of opiorphin transfer was calculated from
areas under curve from the chromatograms representing
the intact opiorphin peptide.
Mass Spectrometry
LC-MS experiments were performed on a nanoAcquity
UPLC (Waters) on-line coupled to an Orbitrap-Elite
(Thermo Scientific) hybrid tandem mass spectrometer oper-
ated in the positive ion mode. Five ml of the samples con-
taining the peptide was injected onto a trapping column
(Waters Symmetry C18; 180 mm  20 mm, 5 mm particle
size) and after washing with 1% solvent B for 5 min was
transferred onto the separating column (Dionex Acclaim
PepMap; 75 mm  25 cm, 2 mm particle size, 100 A pore
size) developing a linear gradient of 1e35% solvent B in
10 min using a flow rate of 200 nl/min (solvent A: 0.1% for-
mic acid/water; solvent B: 0.1% formic acid/acetonitrile).
For MS experiments, mass range of m/z: 200e600 was
monitored at resolution of 60000 using internal calibration
to the background polysiloxane ion (m/z: 445.120024).
Relative quantity of opiorphin was estimated using the ex-
tracted ion chromatogram (XIC) of m/z: 347.1932 (5
ppm) peak intensity corresponding to the doubly charged
opiorphin peptide cation.
Results
MS/MS characterization of the synthetic opiorphin peptide
was performed using both collision-induced dissociation
and higher energy collisional activation. The observed m/
z value of the protonated peptide ions and fragmentation
pattern were in good agreement with those expected for
the QRFSR sequence. Signal intensities in the receiver
compartment samples were 1e2  106 as opposed to 1.5
 108 in the donor compartment samples (Figure 2).
The relative quantity of opiorphin that penetrated through
the BBB model was calculated to be 2.91  1.13% based on
the area under curve of the doubly charged opiorphin peptide
ion m/z 347.1932. As a comparison, 0.41  0.03% of fluo-
rescein and 0.03 0.01% of albumin crossed the brain endo-
thelial cell layers in parallel inserts from the same cell
isolation under identical assay conditions.
The clearance of opiorphin is shown in Figure 1C. Papp
of opiorphin was 0.53  1.36  106 cm/s (n 5 4). In par-
allel inserts from the same cell isolation under identical
assay conditions the Papp of fluorescein was 1.03  0.09
 106 cm/s (n 5 4) and that of albumin 0.07  0.04 
106 cm/s (n 5 4).
We also observed rapid conversion of N-terminal gluta-
mine into pyroglutamic acid both in 0.1% formic acid and
in Ringer-Hepes buffer used for BBB penetration experi-
ments. We monitored the pyroglutamic acid-containing
peptide using its calculated molecular mass [monoisotopic
MW: 675.3453 yielding a doubly charged protonated pep-
tide ion m/z:338.6799 (z 5 2)].
Discussion
We measured the transfer of opiorphin across a BBB cul-
ture model for the first time. The resistance data and Papp
Figure 2. Extracted ion chromatograms of m/z: 347.1932  5 ppm corre-
sponding to the doubly charged peptide ion of opiorphin. Upper panel: sam-
ple from the receiver compartment (‘‘brain side’’) after 30 min incubation,
middle panel: sample from the receiver compartment after 60 min incuba-
tion, bottom panel: sample from the donor compartment (‘‘blood side’’) after
60 min incubation. Peak labels denote retention time and m/z value.
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values for passive hydrophilic permeability markers fluo-
rescein and albumin were in accordance with our previous
data and indicated a tight barrier (16,17). Instead of radio-
labeling we used the native form of the peptide and a
sensitive method, LC-MS, to detect opiorphin. A mass
spectrometry method was already applied for the quantifi-
cation of opiorphin in human saliva (18). Our data indicate
that opiorphin crosses the BBB in vitro in the absence of
plasma factors at a slow rate, which is lower than that of
the paracellular marker fluorescein but higher than that of
the passive transcellular marker albumin. At the same time
the extent of penetration was significant, |3% in contrast to
the low amount of the paracellular markers. As a compari-
son, numerous endogenous peptides or regulatory proteins
have !0.1%/g uptake in brain and are still effective in
the CNS after peripheral administration (12e14,19).
Among the opiates, the centrally active morphine has an
uptake of only !0.02%/g brain (20).
The amount of opiorphin transferred across the BBB
culture model indicates that a specific transport mechanism,
a peptide transport system or receptor-mediated transcyto-
sis, may be involved in its transfer. Six transport systems
(PTS1-6) have been identified for peptides at the BBB,
which transport enkephalins, arginine vasopressin, or pitui-
tary adenylate cyclase-activating polypeptides, among
others (11). The peptide/histidine transporter 2 (PHT2,
SLC15a3) was described at the BBB carrying di- and tri-
peptides, whereas larger peptides or proteins like insulin
or transferrin cross the BBB by receptor-mediated transcy-
tosis (15). To reveal if carriers or transporters participate in
opiorphin transfer, further experiments are needed.
We observed the conversion of N-terminal glutamine
into pyroglutamic acid in the peptide samples. Peptide
N-terminal glutamines are prone to cyclization yielding py-
roglutamic acid. This reaction can be catalyzed enzymati-
cally by cyclization of L-glutamine and L-glutaminyl
peptides (21), but the reaction also happens spontaneously,
especially at acidic pH values. The presence of glutaminyl
cyclase is described in brain but not known at the level of
brain capillaries and there are no data on how pyrogluta-
mate formation modifies the transport of peptides across
the BBB. The tripeptide thyrotropin-releasing hormone
contains a pyroglutamate and has a slow, but in vivo
measurable penetration across the BBB (22).
The relative quantity of opiorphin penetration through
the BBB culture model is obviously more elevated than
values obtained with iv-administered labeled opioid pep-
tides (14). A possible explanation for this difference is that
in our culture system no serum factors were present during
the experiments, which is a limitation of the model. Pepti-
dases are active in blood and rapidly cleave the native
opiorphin peptide, which has a metabolic half-life of 6
min in human plasma; therefore, enzyme activity limits
the transfer of opiorphin to the CNS in vivo (4,23,24).
In vivo data suggest that even in the presence of serum
peptidases opiorphin can cross the BBB in sufficient
amounts to raise the concentration of endogenous opioid li-
gands by inhibiting enkephalinases; thus, it can be appro-
priate for producing central effects.
In conclusion, our results indicate that opiorphin crosses
cultured brain endothelial cells. These data are in agreement
with observations that opiorphin potentiates enkephalin-
mediated antinociception and exerts antidepressant-like
effects. We suggest that opiorphin may have a potential for
further development as a centrally acting novel drug for
the treatment of pain or depression.
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a b s t r a c t
The intercellular junctions restrict the free passage of hydrophilic compounds through the paracellular
clefts. Reversible opening of the tight junctions of biological barriers is investigated as one of the ways to
increase drug delivery to the systemic circulation or the central nervous system. Six peptides, ADT-6,
HAV-6, C-CPE, 7-mer (FDFWITP, PN-78), AT-1002, and PN-159, acting on different integral membrane
and linker junctional proteins were tested on Caco-2 intestinal epithelial cell line and a coculture model
of the bloodebrain barrier. All peptides tested in nontoxic concentrations showed a reversible tight
junctions modulating effect and were effective to open the paracellular pathway for the marker mole-
cules ﬂuorescein and albumin. The change in the structure of cellecell junctions was veriﬁed by im-
munostaining for occludin, claudin-4,-5, ZO-1, b-catenin, and E-cadherin. Expression levels of occludin
and claudins were measured in both models. We could demonstrate a selectivity of C-CPE, ADT-6, and
HAV-6 peptides for epithelial cells and 7-mer and AT-1002 peptides for brain endothelial cells. PN-159
was the most effective modulator of junctional permeability in both models possibly acting via
claudin-1 and -5. Our results indicate that these peptides can be effectively and selectively used as
potential pharmaceutical excipients to improve drug delivery across biological barriers.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Introduction
Biological barriers are crucial to protect organisms from harmful
agents or pathogens and to establish and maintain the homeostasis
of different organs, especially those of the central nervous system.1,2
However, the same mechanisms of epithelial and endothelial bar-
riers that confer protection also restrict drug absorption and de-
livery.1,3 Active efﬂux transporters not only protect from the harmful
effects of xenobiotics but also prevent the penetration of therapeutic
drugs.4 Metabolic enzymes represent another element of the pro-
tective system of barriers.5 In addition, tight intercellular junctions
(TJs) limit the free passage of molecules and cells through the
intercellular clefts, also called as the paracellular pathway.1 Because
the noninvasive delivery of hydrophilic drugs or biopharmaceuticals
to the systemic circulation or to the central nervous system is still a
challenge, several methods have been investigated to increase drug
delivery across barriers.3 Absorption enhancers including clinically
applied and novel excipients are effective to increase drug perme-
ability across both epithelial and endothelial cell layers6; however,
these act nonselectively on biological barriers7 and modulate both
the tightness of intercellular junctions and the ﬂuidity of the plasma
membrane.8
TJs of barrier cells are complex structures composed of integral
membrane proteins, linker proteins connecting membrane proteins
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to the actin cytoskeleton, and signaling molecules regulating para-
cellular tightness and transport.9 Among the transmembrane TJ
proteins occludin and the members of the claudin family have a
prominent role in forming paracellular barriers.10 Adherens junction
proteins, such as E-cadherin in epithelial cells or VE-cadherin in
endothelial cells, also participate in the regulation of paracellular
permeability.11 Based on the amino acid sequence and/or the struc-
ture of these junctional proteins, peptides were designed as novel TJ
modulators that directly and speciﬁcally interact with the extracel-
lular loops (ECLs).12
In our study, 6 different modulator peptides were selected
(Table 1) which act at different targets.1 Two hexameric peptides,
ADT-6 and HAV-6, were designed to act on the bulge and groove
regions of the ﬁrst extracellular domain (EC-1) of E-cadherin.13
These peptides interfere with the homophilic binding of E-cad-
herin, and time- and dose-dependently increase the paracellular
permeability in different epithelial cells.14,19 Two TJ modulators
used in the experiments are derived from microbial toxins. The C-
terminal 16-residue long fragment of Clostridium perfringens
enterotoxin (C-CPE) targets claudins.15 C-CPE acts speciﬁcally at the
ECL2 of claudin-4 and -3 to increase intestinal permeability in vivo
and in vitro.20,21 AT-1002 peptide, an active fragment of zonula
occludens toxin, a Vibrio cholerae enterotoxin, increases the
permeability of epithelial, especially intestinal barriers,16 similar to
the full length microbial pathogenic factor.22 The last 2 peptides,
7-mer (PN-78) and PN-159, were identiﬁed on ethylene glycol
tetraacetic acid (a calcium chelating reagent)etreated human
bronchial epithelial cells by phage display.17,18 PN-159 effectively
increases the permeability of respiratory epithelium in cultures and
in animals.23 The speciﬁc targets of these peptides are unknown;
they probably interact with the extracellular domain of integral
membrane TJ protein(s). These 6 peptideswere not investigated in a
comparative way for their efﬁcacy on the same model or for their
speciﬁcity on different, epithelial versus endothelial barriermodels.
For our experiments, 2 well-characterized culture models of the
intestinal and the blood-brain barriers (BBBs) were used. The lab-
oratory of Professor Borchardt introduced the Caco-2 cell line as a
model system for intestinal epithelial permeability24 and brain
microvessel endothelial cell monolayers as a model to estimate
solute permeability through the BBB.25 Since the pioneering pub-
lication on Caco-2 cells, the application of this human intestinal
epithelial cell line has become widespread in pharmaceutical
research, especially in drug permeability studies.26 In the ﬁeld of
BBB models, in the last 20 years, monocultures were replaced
by coculture models, in which astrocytes and/or pericytes induce
BBB characteristics in brain endothelial cells.27,28 The primary
cellebased rat BBB in vitro triple coculture model has high
complexity and predictive value for drug penetration and was
favorably compared with surrogate models of the BBB.29,30
TJ modulator peptides hold a great promise as drug absorption
enhancers, but more data are needed on their efﬁcacy, mode of
action, reversibility, and safety before their application in clinical
studies. The expression patterns of tight and adherens junction
proteins are speciﬁc for different types of barriers providing an
opportunity for selective modulation of paracellular permeability,
but this approach remained largely unexploited so far. Because of
these reasons, the aim of the present study was to compare the
efﬁcacy of 6 selected TJ modulator peptides on culture models of
both the intestinal barrier and the BBB. In addition to barrier
integrity measurements, cell morphology was also investigated.
Because safety is a crucial parameter, cellular toxicity and revers-
ibility was alsomeasured. For the selective applications of peptides,
the mode of action and/or the target of the TJ modulator is needed;
therefore, the potential binding partners of the peptides discovered
by phage display were investigated.
Materials and Methods
Materials
All reagents were purchased from Sigma-Aldrich Ltd. (Budapest,
Hungary) except for those speciﬁcally mentioned.
Peptide Synthesis
The sequence of peptides is shown in Table 1. Peptides were
synthesized manually on a 0.5-mM scale with the use of standard
Fmoc-chemistry on a Rink-amide resin. Couplings were performed
in dimethylformamide with 3-fold excess of N,N0-dicyclohex-
ylcarbodiimide, hydroxybenzotriazole, and Fmoc-amino acids for 3
h at ambient temperature. Fmoc deprotection was performed in
20% piperidine and dimethylformamide mixture for 20 min. The
peptides were cleaved from the resin by incubating it with the
mixture of triﬂuoroacetic acid (TFA)/water/triisopropyl silane
(48:1:1) at room temperature for 3 h, precipitated andwashedwith
diethyl-ether, and then, lyophilized. Crude peptides were puriﬁed
using a Shimadzu semipreparative high-performance liquid chro-
matography system equipped with a Phenomenex Jupiter C18
column in the following solvent system: (A) 0.1% aqueous TFA and
(B) 0.1% TFA in 80% aqueous acetonitrile, in a linear gradient mode.
Analysis and purity control was carried out on an analytical HPLC
instrument (HP Model 1100 liquid chromatograph equipped with a
Phenomenex Jupiter C18 column). Quality control of the peptides
was done by performing mass spectrometric measurements on a
Finnigan TSQ-7000 triple quadrupole mass spectrometer in posi-
tive ion mode.
Cell Cultures
Human Caco-2 intestinal epithelial cell line (ATCC cat.no. HTB-
37) selected by vinblastine was used until passage 60 for the ex-
periments. Vinblastine treatment (10 nM for 6 passages) induced
more homogeneous cell morphology and higher expression level of
efﬂux pumps.31 Caco-2 cells were grown in DMEM/HAM’s F-12
culture medium with stable glutamine (Biochrom GmbH, Berlin,
Germany) supplemented with 10% fetal bovine serum (Pan-Biotech
GmbH, Aidenbach, Germany) and 50-mg/mL gentamycin in a hu-
midiﬁed incubator with 5% CO2 at 37C. All plastic surfaces were
coated with 0.05% rat tail collagen in sterile distilled water before
cell seeding.
Table 1
Characteristics of the Selected Modulator Peptides
Peptide Target Mechanism Amino Acid Sequence Derived From Reference
ADT-6 E-cadherin EC1 domain analogue Ac-ADTPPV-NH2 Designed to target EC1 domain 13
HAV-6 E-cadherin EC1 domain analogue Ac-SHAVSS-NH2 Designed to target EC1 domain 14
C-CPE Claudin-3, -4 Interact with EC1 domain NH2-SSYSGNYPYS ILFQKF-OH Microbial toxin fragment 15
AT-1002 ZO-1 Zot receptor FCIGRL Microbial toxin fragment 16
7-mer/PN-78 Unknown e FDFWITP Phage display 17
PN-159 Unknown e NH2-KLALKLALKALKLAALKLA-amide Phage display 18
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Primary cultures of brain endothelial cells, glial cells, and peri-
cytes, and the in vitro BBB model were prepared according to the
method described in our previous study.29 Brain endothelial cells
were cultured in DMEM/F-12 (Gibco, Life Technologies, Carlsbad,
CA), 15% plasma-derived bovine serum (First Link, Wolverhampton,
UK), 100-mg/mL heparin, 5-mg/mL insulin, 5-mg/mL transferrin,
5-ng/mL sodium selenite, 1-ng/mL basic ﬁbroblast growth factor
(Roche, Basel, Switzerland), and 50-mg/mL gentamycin. During the
ﬁrst 3 days of culture, the medium of brain endothelial cells con-
tained 3-mg/mL puromycin to eliminate P-glycoprotein negative,
contaminating cell types.32 During the experiments, brain endo-
thelial cells were always seeded on surfaces coatedwith 100-mg/mL
collagen type IV and 100-mg/mL ﬁbronectin in sterile distilled wa-
ter. Primary rat brain pericytes were isolated by the same method,
except pericytes were plated onto uncoated Petri dishes (Orange
Scientiﬁc, Braine-l’Alleud, Belgium). Primary cultures of rat glial
cells were prepared from one-day-old Wistar rats32 and passaged
to 12-well dishes (Corning, Costar, New York, NY) coated with 100-
mg/mL collagen type IV in sterile distilled water and cultured for 2
weeks before using the triple coculture model. Pericytes and glial
cells were cultured in DMEM/HAM's F-12 supplemented with 10%
fetal bovine serum (Pan-Biotech GmbH) and 50-mg/mL gentamycin.
For the triple coculture model, pericytes (P3) were passaged to the
bottom side of 12-well tissue culture inserts (Transwell 3460,
polyester membrane, 0.4 mm pore size; Corning Costar) at a density
of 1.5  104 cells/cm2. Endothelial cells were seeded to the upper
side of the membranes (8  104 cells/cm2) and placed to 12-well
plates containing glial cells. Both compartments received endo-
thelial culture medium, and the 3 types of cells were cultured
together for 4 or 5 days.29,33 When brain endothelial cell layers
became conﬂuent, 550-nM hydrocortisone was added to tighten
the junctions.34 For experiments with Caco-2 cells, passage
numbers were close to each other. For the BBB model, primary
cultures were obtained from several isolations, but the barrier pa-
rameters were very similar in the assays.
Peptide Treatment
The stock solutions (10 mM) were prepared freshly, ADT-6, HAV-
6, C-CPE, and AT-1002 peptides were dissolved in sterile distilled
water, whereas 7-mer PN-78 and PN-159 peptides were dissolved in
sterile DMSO. Treatment solutions were further diluted in Ringer-
Hepes (150-mM NaCl, 6-mM NaHCO3, 5.2-mM KCl, 2.2-mM CaCl2,
0.2-mM MgCl2, 2.8-mM D-glucose, 5-mM Hepes; pH 7.4) or cell
culture medium. Peptide concentrations were selected based on
references shown in Table 1. In a previous study, both E-cadherin
peptides were used at 1-mM concentration.13 In our tests, 1-mM
concentration of ADT-6 or HAV-6 did not increase the permeability
of Caco-2 cell layers for ﬂuorescein; therefore, 2-mM was used,
which enhanced the permeability but showed no toxicity
(Supplementary Figs. S1 and S2). C-CPE peptide was effective in
1-mM concentration without negative inﬂuence on the cell viability
(Supplementary Figs. S1 and S2). Caco-2 cells were treated with
AT-1002 peptide in higher (5mM) concentrations in another work,16
but brain endothelial cells were sensitive even for 2 mM for longer
treatments (Supplementary Fig. S3); therefore, 2mMwas selected as
a safe concentration for 1 h on both models (Supplementary Figs. S1
and S2). In the case of 7-mer PN-78, we applied 100-mM concen-
tration, which was also used in bronchial epithelial cells.17 PN-159
was used at 10-mM concentration, which was effective on epithe-
lial cells.18 Higher concentrations were toxic on both models
(Supplementary Figs. S1 and S2). Final concentrations of the peptides
in treatment solutions were as follows: 2 mM for ADT-6, HAV-6, and
AT-1002 peptides; 1 mM for C-CPE peptide; 100 mM for 7-mer
peptide; and 10 mM for PN-159 peptide.
Cell Viability Assays
For the cell viability assays, Caco-2 epithelial cells and rat
brain endothelial cells were seeded to 96-well plates at the density
of 6  103 cells/well (Orange Scientiﬁc) and cultured for 3-5 days.
Conﬂuent cultures were treated with peptides in phenol red free
DMEM (Life Technologies, Gibco) for 1 h. To determine the 100%
toxicity, cells were incubated with 1mg/mL Triton X-100 detergent.
After treatment, the medium was changed and 0.5-mg/mL 3-(4,5-
dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution was added to the cells for 3 h in a CO2 incubator. The
metabolic activity of cells is reﬂected by the conversion of the
yellow MTT dye to purple formazan. Formazan crystals were dis-
solved in DMSO, and the amount of converted dye was determined
by measuring the absorbance at 595 nm wavelength with a
microplate reader (Fluostar Optima; BMG Labtechnologies, Orten-
berg, Germany). Cell viability and/or metabolic activity was calcu-
lated as the percentage of dye conversion by nontreated cells.
Kinetics of epithelial and endothelial cell reaction to peptide
treatment were monitored by impedance measurement at 10 kHz
(RTCA-SP instrument; ACEA Biosciences, San Diego, CA). Imped-
ance measurement is label-free, real time, noninvasive, and corre-
lates linearly with adherence, growth, number, and viability of
cells.6,35 For background measurements, 50-mL cell culture medium
was added to the wells, then cells were seeded at a density of 6 
103 cells/well to coated 96-well plates with integrated gold elec-
trodes (E-plate 96, ACEA Biosciences). Cells were cultured for 5-7
days in CO2 incubator at 37C andmonitored every 10 min until the
end of experiments. At the beginning of plateau phase of growth,
cells were treated with peptide solutions, and the effects were
followed for 24 h. Triton X-100 detergent (1 mg/mL) was used as a
reference compound inducing cell toxicity. Cell index was deﬁned
as Rn-Rb at each time point of measurement, where Rn is the cell-
electrode impedance of thewell when it contains cells and Rb is the
background impedance of the well with the medium alone.
Measurement of the Integrity of the Paracellular Barrier
Transepithelial or transendothelial electrical resistance (TEER)
reﬂects the tightness of the intercellular junctions.36 TEER was
measured by an EVOM volt-ohmmeter (World Precision In-
struments, Sarasota, FL) combined with STX-2 electrodes and was
expressed relative to the surface area of the monolayers, U  cm2.
Resistance of cell-free inserts (130 U  cm2) was subtracted from
the measured values.
For permeability tests, Caco-2 cells were seeded onto Transwell
inserts and cultured for 3 weeks.8,30 The BBB model was used after
4-5 days of coculture. For both models, culture medium was
changed and resistance was checked every second day. For the
experiment, inserts were transferred to 12-well plates containing
1.5-mL Ringer-Hepes buffer in the lower (basal and/or abluminal)
compartments. In the upper (apical and/or luminal) compartments,
culture medium was replaced by 0.5-mL buffer containing peptide
solutions for 1 h. Permeability marker molecules albumin (1 mg/
mL; molecular weight: 65 kDa) labeled with Evans blue (167.5 mg/
mL) and ﬂuorescein (10 mg/mL; molecular weight: 376 Da) were
added 30 min later. The incubation with permeability markers in
the presence of peptides lasted for 30 min. Samples were collected
from both compartments, and the concentrations of the marker
molecules were determined by a ﬂuorescence multi-well plate
reader (Fluostar Optima; excitation wavelength: 485 nm, emission
wavelength: 535 nm in the case of ﬂuorescein and excitation
wavelength: 584 nm, emission wavelength: 680 nm in the case of
Evans blueelabeled albumin). To test the reversibility of the pep-
tide effect, inserts with the cells were placed back to the culture
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plates containing medium after the permeability tests. Treatment
solutions from the upper compartments were removed and after a
gentle wash were changed for culture medium. Cells were kept in a
CO2 incubator at 37C for 24 h; then, after the measurement of
TEER, the permeability experiments were repeated.
The apparent permeability coefﬁcients (Papp) were calculated as
described previously.8,35 Brieﬂy, cleared volume was calculated
from the concentration difference of the tracer in the lower and/or
basal compartment (D[C]B) after 30 min and upper and/or apical
compartments at 0 h ([C]A), the volume of the lower and/or basal
compartment (VB; 1.5 mL), and the surface area available for
permeability (A; 1.1 cm2).
Immunohistochemistry
Morphologic changes in epithelial and endothelial barrier
integrity were followed by immunostaining for integral membrane
tight junction proteins occludin and claudin-5, adherens junction
protein E-cadherin, and cytoplasmic linker proteins b-catenin and
zonula occludens protein-1 (ZO-1). After permeability tests, inserts
were washed with phosphate-buffered saline (PBS). In the case of
BBB, model pericytes were removed from the bottom of the
membranes, then brain endothelial or epithelial cells were ﬁxed
with 1:1 mixture of ice cold acetone and methanol for 10 min at
room temperature. Cells were blocked with 3% bovine serum al-
bumin in PBS and incubated with primary antibodies rabbit anti-
occludin, mouse anti-claudin-5, mouse anti-E-cadherin, rabbit
anti-ZO-1, and rabbit anti-b-catenin (Life Technologies) overnight.
Incubation with secondary antibodies Alexa Fluor-488elabeled
anti-mouse (Life Technologies, Invitrogen) and Cy3-labeled anti-
rabbit lasted for 1 h. Hoechst dye 33342 was used to stain cell
nuclei. After mounting the samples (Fluoromount-G; Southern
Biotech, Birmingham), staining was visualized by a Leica TCS SP5
confocal laser scanning microscope (Leica Microsystems GmbH,
Wetzlar, Germany).
Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)
Gene expression analysis was performed as described recently
by our group.33,37 Conﬂuent cultures were washed, scraped, and
collected, and cell pellets were used for total RNA isolation using
RNAqueous-4PCR Kit (Life Technologies, Ambion, Austin, TX). cDNA
synthesis was performed by High Capacity cDNA Reverse Tran-
scription Kit (Life Technologies). The expression of occludin and the
selected claudin genes were analyzed by quantitative PCR using
TaqMan Low Density Array 384-well microﬂuidic cards preloaded
with inventoried TaqMan Gene Expression Assays (Supplementary
Table S1; Life Technologies, Applied Biosystems, Austin, TX).
Expression of all genes was normalized to the 18S ribosomal RNA as
endogenous control, highly expressed in eukaryotic cells. Expres-
sion values of studied genes were determined by the correlation of
normalized expression of genes calculated by 2DCt formula to the
lowest expression level which can be safely detected by this RT-PCR
method.
Microscale thermophoresis
Association between peptide and claudins was measured with
microscale thermophoresis.38 The claudins carried yellow ﬂuores-
cence protein,39 and the peptide was added in deﬁned amounts as
titration series (in PBS, 15 dilutions). After incubation (1 h, 22C),
samples were loaded into standard treated capillaries, and ﬂuo-
rescence was measured with Monolith™ NT.115 (light-emitting
diode power 50%, infrared laser power 80%, laser-on time 35 s).
Evaluation was performed with NT Analysis software 1.2.229
(NanoTemper, Munich, Germany). Binding was characterized by
dissociation constant (Kd). Determination was achieved using
saturation-binding curves obtained at equilibrium.40
Molecular Modeling
Protein structures were obtained by homology modeling using
the MODELLER program package.41 First, the structure of mouse
claudin-15 was completed by homology modelling because its
X-ray structure ﬁle is lacking the fragment of residues from 34 to
41.42 Human claudins 1, 3, and 5 were homology modeled using
the completed mouse claudin-15 as a template. The protein ho-
mology models were further relaxed by a short (400 ns) molec-
ular dynamics simulation in which the proteins were embedded
in a 95 by 95 Å POPC bilayer-water system containing 150-mM
NaCl. Molecular dynamics simulations were performed by the
program NAMD,43 using the CHARMM27 molecular force ﬁeld
with CMAP correction. The results were visualized by VMD,
v1.9.1.44 The docking studies were performed by the CABS
docking server,45 and the resulted C-alpha traces were recon-
structed by MODELLER using the python script supplied by the
server homepage.
Statistical Analysis
For statistical analysis, GraphPad Prism 5.0 software (GraphPad
Software Inc., San Diego, CA) was used. All data presented are
means ± SD. Values were compared using ANOVA followed by
Dunnett’s test and t test. Changes were considered statistically
signiﬁcant at p < 0.05. All measurements were repeated 3 times,
and the number of parallel samples in the experiments (n) was 3-6,
which depended on the type of assays.
Results
Effect of Tight Junction Modulator Peptides on Cell Viability
Based on the colorimetric end point, dye conversion MTT assay
treatments with peptides ADT-6, HAV-6, and AT-1002 in 2 mM;
C-CPE in 1 mM; 7-mer in 100 mM; and PN-159 in 10 mM concen-
trations for 1 h did not cause signiﬁcant change in the metabolic
activity of Caco-2 epithelial (Fig. 1a) or brain endothelial cells
(Fig. 1b). Impedance measurement, a sensitive method to detect
cellular effects, revealed no decrease for a 1-h treatment in Caco-2
cells (Fig. 1c). Brain endothelial cells were more sensitive; ADT-6,
HAV-6, and AT-1002 peptides caused 15%-20% decrease in cell
layer impedance after 1-h treatment. As a comparison, Triton X-100
caused 100% toxicity in both assays (Fig. 1).
Long-term effect of peptides on epithelial and endothelial bar-
riers was also determined (Supplementary Fig. S3). In Caco-2 layers,
no change was seen in impedance except for a temporary increase
after PN-159 peptide treatment. In brain endothelial cells, only AT-
1002 and C-CPE peptides decreased signiﬁcantly the cell index after
24 h. The effects of peptides with scrambled sequences were tested
on epithelial cells, and no change in cell index was seen until 24 h
(Supplementary Fig. S4).
Effect of Tight Junction Modulator Peptides on Barrier Integrity
All 6 peptides signiﬁcantly decreased the TEER of Caco-2
layers after 1-h treatment (Fig. 2a). Treatments with ADT-6, C-
CPE, and PN-159 reduced the resistance of cell layers by more than
50%, whereas 7-mer, HAV-6, and AT-1002 caused a 30%-45%
drop as compared with control (1309 ± 97 U  cm2). The resis-
tance of brain endothelial monolayers was also decreased by the
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peptides, except C-CPE peptide, which had no signiﬁcant effect
(Fig. 2b). The TJ modulator peptides caused less than 50% reduc-
tion of TEER compared with control (314 ± 48 U  cm2). PN-159
peptide was the most effective on both models (Fig. 2). Barrier
integrity was recovered in both models in all treatment groups
after 24 h.
The modulator peptides increased the permeability of Caco-2
layers for ﬂuorescein and albumin markers (Figs. 3a and 3b).
ADT-6, HAV-6, and especially PN-159 peptides were the most
effective. PN-159 peptide increased the epithelial permeability
for ﬂuorescein more than 200-fold and for albumin around 30-
fold. The 7-mer peptide had no effect on ﬂuorescein ﬂux, but
increased the permeability of albumin. Scrambled peptides had
no inﬂuence on intestinal barrier integrity. Neither ﬂuorescein
nor albumin permeability changed after 1-h treatment
(Supplementary Fig. S5).
On the BBB model, AT-1002, 7-mer, and PN-159 peptides
signiﬁcantly enhanced the permeability of both markers (Figs. 3c
and 3d). AT-1002 and 7-mer peptides increased the ﬂux of
markers 3.5 to 6-fold, whereas PN-159 peptide showed the highest
effect with about 10-fold increase. In the BBB model, E-cadherin
peptides had a small effect on ﬂuorescein, but not on albumin
penetration, whereas C-CPE had no effect (Figs. 3c and 3d).
Permeability assays were repeated after 24-h recovery, and the
TJ modulating effect of the peptides were reversible on both Caco-2
and BBB models (Fig. 3).
Effect of Modulator Peptides on the Morphology of Intercellular
Junctions
In both culture models, the cells were tightly apposed and
all junctional proteins were localized at the intercellular connec-
tions forming pericellular belts in control groups (Figs. 4 and 5). The
E-cadherin peptides had robust effects on junctions of Caco-2 cells,
fragmentation of b-catenin and E-cadherin stainings at the cell
border and redistribution of the immunostaining to the cytoplasm
were observed (Fig. 4). Microbial toxin C-CPE peptide caused visible
changes in ZO-1, b-catenin, and occludin immunostaining, labeling
at the cell borders markedly decreased. AT-1002 and 7-mer pep-
tides had slight effect on these junctional proteins. ZO-1 immu-
nolabeling was less changed for peptide treatments, except PN-159.
Epithelial junctional morphology was drastically changed by
PN-159, ZO-1, and b-catenin proteins partially disappeared from
cell borders. Occludin immunostaining in several cells became
absent in cell contacts, enriched in the cytoplasm, and showed
spotty staining pattern (Fig. 4).
All peptides, except C-CPE, inﬂuenced junctional morphology at
the BBB model (Fig. 5). E-cadherin peptides, AT-1002, and 7-mer
peptides had similar effects on immunostaining of ZO-1, b-catenin,
and claudin-5 proteins, labeling was less sharp on cell borders, and
gaps and holes appeared between the cells. PN-159 peptide caused
the biggest change in immunostainings for all 3 proteins in brain
endothelial cell junctions (Fig. 5). A strongdecrease of the staining at
Figure 1. Cell viability assays after 1-hour treatment with tight junction modulator peptides. The toxicity of peptides on Caco-2 intestinal epithelial cells (a) and brain endothelial
cells (b) was measured by MTT dye conversion assay. The effect of peptides on the impedance of epithelial (c) and brain endothelial (d) cell layers is shown as cell index. The MTT
and cell index are given as percent of control (100% viability). Values are presented as means ± SD, n ¼ 3-8. Statistical analysis: ANOVA followed by Dunnett’s test, p < 0.05 as
compared with the control groups.
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the cell border was accompanied by an increase in staining over cell
bodies. The morphologic changes caused by the peptides were
reversible after 24-h recovery in both models.
Gene Expression of Occludin and Claudins
Occludin mRNA was highly expressed in both models (Fig. 6). In
vinblastine-selected Caco-2 cells, the expression of claudin-1, -3, -4,
and -7 genes were the highest, whereas claudin-5, -11, and -19 were
not expressed. In contrast, in brain endothelial cells, claudin-5mRNA
was the most abundant, similar to isolated brain capillary data.46,47
High levels of claudin-11 and -15 and lower levels of claudin-1 and
-3 mRNA were measured in our culture BBB model. Claudin-11 and
-15 mRNA expression was also detected in mouse brain capillary
endothelial cells.46 In freshly isolated mouse brain endothelial cells,
low levels of claudin-146 and claudin-347 mRNAwere described. No
expressionof genes of claudin-7, -8, -14, and -16wasmeasured in the
BBB model. Claudin-18 was not found in the cultures.
Afﬁnity Measurements of Peptides to Claudin Proteins
High-afﬁnity binding of PN-159 was detected by microscale
thermophoresis to claudin-5-YFP (Kd: 327 nM) and claudin-1-YFP
(Kd: 820 nM). Unspeciﬁc binding (Kd >4000 nM) was measured
for claudin-3-YFP and YFP (negative control; Figs. 7a and 7b).
Molecular Modeling of Claudin-1, -3 and -5 and Docking PN-159
Peptide to the Extracellular Portion
Docking of PN-159 peptide to full length homology-modeled
human claudin monomers 1, 3, and 5 was performed on the CABS
server. Favorable docking poses were seeked by both energetic and
geometric considerations. Docking poses located around ECLs and
the short extracellular helix of the proteins were analyzed in all
docking trajectories. Docking energies (“total energy”) were
decomposed to “ligand energy,” “interaction energy,” and “receptor
energy” parts (Supplementary Table S2). Correct docking poses
were expected to have low values not only for the total energies but
also as low as possible for all energy components simultaneously.
Thus, the “ligand energy,” “interaction energy,” and “total energy”
values were investigated. For comparison, total energies were
normalized in the sense that, for each claudin, the total energy was
decreased by the maximum value of the total energy. Based on the
modeling, energetically highly favorable interactions were found
between PN-159 and the ECL1 of claudin-5 and claudin-1 but not for
claudin-3 (Supplementary Table S2). The energy values from
modeling correlate well with the rank order of the binding of PN-
159 to the tested claudins (Figs. 7a). Docked poses of PN-159 with
ECL1 of claudin-1 and -5 are shown on Figures 7c and 7d. In case of
human claudin-1, the following residues participate in major in-
teractions with PN-159 peptide: K65 with L19 (polar) and D68 with
K20 (ionic). In addition, N39, I40, and Q44 form a hydrophobic
pocket accomodating L5 of the peptide (Fig. 7c). This later interac-
tion may contribute to the disappearance of b-strands 1 and 5. Two
major interactions were observed between claudin-5 ECL1 and PN-
159 peptide: Q63 with K12 (polar) and a stronger ionic interaction
between D68 and K1 (Fig. 7d). Binding of PN-159 to claudin-5 dis-
rupted all b-strands in ECLs. Supplementary Fig. S6 shows a docking
pose of PN-159 to claudin-5 with a weaker, but still more favorable,
total energy as compared to claudin-1 and -3 (Supplementary
Table S2). In this case, 2 polar interactions were found between
N39 and K9 and Q57 and K17 leaving all b-strands intact.
Discussion
This study compared for the ﬁrst time the effects of 6 modulator
peptides acting on different targets on 2 culture models of different
barriers, namely the intestinal and the BBBs. All peptides induced
reversible opening of junctions, but selectivity and differences in
efﬁcacy were observed. Potential targets of the most effective
peptide PN-159 were identiﬁed as claudin-5 and -1 by afﬁnity
measurement and molecular modeling.
Peptides Acting on E-cadherin
Peptides HAV-6 designed for the bulge and ADT-6 designed for
the groove regions of the EC1 domain of E-cadherin13 increased the
permeability for marker molecules and decreased the TEER on
Caco-2 intestinal cell layers (Figs. 2 and 3). Our results are similar to
those described on MDCK13 and Caco-2 epithelial cells.14 We veri-
ﬁed that the TJ modulator effect is reversible for both peptides. Full
recovery of the barrier properties was also proved by immuno-
staining (Fig. 4). Both peptides decreased TEER and induced
reversible changes in immunostaining on the BBB model, but only
ADT-6 induced an increase in paracellular permeability for the
small marker. In contrast to epithelial cells, ADT-6 did not change
the ﬂux of albumin, and HAV-6 had no effect on the permeability of
markers in cultured endothelial cells. A possible explanation for the
Figure 2. Effects of modulator peptides on the resistance of Caco-2 epithelial (a) and
brain endothelial (b) cell layers. White columns represent the effect of 1-h peptide
treatment and gray columns show resistance after 24-h recovery. Data are presented as
means ± SD, n ¼ 3-6. Statistical analysis: ANOVA followed by Dunnett's
test. Statistically signiﬁcant differences are: *p < 0.05, compared to control group
(Caco-2: 1309 ± 97 U  cm2; BBB: 314 ± 48 U  cm2); #p < 0.05 compared to control
group value 24-h later (Caco-2: 1338 ± 53 U  cm2; BBB: 350 ± 60 U  cm2).
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different action of the peptides on the 2 culture models could be
that E-cadherin, speciﬁc for epithelial cells, contains the HAVmotif,
a classical cadherin-binding motif in the EC1 domains of type I
subfamily members, but vascular endothelial VE-cadherin
expressed in brain endothelial cells,48 a member of the classical
type II subfamily, lacks this motif.49
Peptides Mimicking Microbial Toxins
AT-1002 peptide acting on ZO-1 cytoplasmic TJ linker protein
decreased resistance on bothmodels and increased the permeability
particularly in thecaseof BBB,which is anewobservation (Figs. 2 and
3). Our results are in agreement with previous studies showing that
this peptide increases the permeability of epithelial barriers.16,50 In
thepresentwork, AT-1002wasexamined in lower concentrationand
with shorter incubation time than in previous studies16,51 because
brain endothelial cells seemed to be more sensitive to the peptide
effect than epithelial cells based on the impedance measurements
(Fig. 1 and Supplementary Fig. S3). AT-1002 peptide treatment
caused visible but not remarkable changes in immunostaining for all
the junctional proteins examined including ZO-1 in both models
indicating a marked effect on paracellular junctions (Figs. 4 and 5).
Importantly, these changes were reversible on both cell types.
We observed that C-CPE peptide signiﬁcantly decreased the
transepithelial resistance and increased the permeability of Caco-2
cell layers for marker molecules in agreement with literature
data.52 The effects on Caco-2 cells were reversible, similar to data
obtained on MDCK kidney epithelial cells.15 In contrast to Caco-2
cells, C-CPE, which was tested on the BBB model for the ﬁrst time,
did not act on brain endothelial cells. This clostridium toxin peptide
fragment increases intestinal permeabilitymainly through claudin-3
and -4, but it cannot bind to claudin-1 and -5 because of its struc-
ture.53,54 Expression level of claudin-3 and -4 is high in epithelial, but
low in brain endothelial cells, explaining our results (Fig. 6).
Peptides Selected by Phage Display
The 7-mer peptide decreased the transepithelial resistance
without changing ﬂuorescein penetration on Caco-2 cell layers in
concordance with data on 4 different epithelial cell lines including
Figure 3. Evaluation of barrier integrity on Caco-2 epithelial (a, b) and brain endothelial cell layers (c, d). Permeability for ﬂuorescein (a, c) and for albumin (b, d) after 1-h treatment
with modulator peptides and after 24-h recovery. White columns represent the effect of 1-hour peptide treatment and gray columns show permeability after 24-h recovery. Values
of apparent permeability coefﬁcients (Papp) in the respective control groups were ﬂuorescein Papp in Caco-2: 0.20 ± 0.02  106 cm/s, and 0.30 ± 0.02  106 cm/s (a); albumin Papp
in Caco-2: 0.26 ± 0.01  106 cm/s, and 0.27 ± 0.01  106 cm/s (b); ﬂuorescein Papp in BBB model: 3.10 ± 0.26  106 cm/s and 3.42 ± 0.62  106 cm/s (c); albumin Papp in BBB
model: 1.59 ± 0.23  106 cm/s and 1.61 ± 0.57  106 cm/s (d). Data are expressed in the % of control groups. Values are presented as means ± SD, n ¼ 3-6. Statistical analysis:
ANOVA followed by Dunnett's test and t test. Statistically signiﬁcant differences were detected after treatment with peptides (p < 0.05) as compared with the control group (*) and
compared with each peptide (#) after recovery.
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Caco-2 cells.17 Interestingly, albumin ﬂux was increased after
peptide treatment, indicating a mechanism other than the para-
cellular transport route, which is also supported by the visibly
intact intercellular junctions. This peptide, with unidentiﬁed target,
was not studied on endothelial cells previously; therefore, our
study is the ﬁrst to show that the 7-mer peptide increases the
permeability for small and large marker molecules on a coculture
BBB model. Our results revealed that endothelial cell junctions are
Figure 4. Effects of modulator peptides on junctional morphology of Caco-2 cells. Immunostaining for occludin and zonula occludens-1 (ZO-1) tight junction proteins, and b-
catenin and E-cadherin adherens junction proteins after 1-h peptide treatment and 24-h recovery. Red color: immunostaining for ZO-1, b-catenin, and occludin. Green color:
immunostaining for E-cadherin. Blue color: staining of cell nuclei. Bar ¼ 25 mm.
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more responsive to 7-mer peptide than Caco-2 cell junctions
(Figs. 2-5).
The other peptide selected by phage display, PN-159, was the
most effective modulator of junctional permeability in both models
(Figs. 2-5). This peptidewas characterized as an effectivemodulator
of airway epithelial TJs in vitro and in vivo.18,23 The effect of PN-159
in the same concentration as in our study was more similar on
bronchial epithelial cells than on Caco-2 cells.18 However, until the
present work therewere no data on its effect on the BBB. This stable
peptidewith a low cytotoxicity proﬁle and fully reversible action on
different cell types has a potential for therapeutic application.
Because PN-159 peptide was originally discovered by phage
technology on bronchial epithelial cell layers in which TJ proteins
were made accessible by removal of calcium, its binding partner
remained unknown so far. Our afﬁnity measurements (Fig. 7a and
7b) revealed that claudin-5 and claudin-1, but not claudin-3, can be
among the potential targets of PN-159. Similar afﬁnity values as
well as epithelial and endothelial barrier opening activity have
been observed for the claudin peptidomimetic C1C2,55 further
supporting the potential of our approach. Based on the afﬁnity-
binding measurement of PN-159 to full length human claudin-1,
-3, and -5, we wanted to reveal the binding mode of the peptide
by docking to claudin monomers (Fig. 7c and 7d). PN-159 has a
unique structure composed of only positively charged and
Figure 5. Effects of modulator peptides on junctional morphology of brain endothelial cells. Immunostaining for claudin-5 and ZO-1 tight junction proteins and b-catenin adherens
junction protein after 1-h peptide treatment and 24-h recovery. Red color: immunostaining for ZO-1 and b-catenin. Green color: immunostaining for claudin-5. Blue color: staining
of cell nuclei. Bar ¼ 25 mm.
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hydrophobic residues. The ionic interaction between lysins of the
peptide and D68 of claudin-1 and -5may be crucial in the biological
effects of the peptide (Supplementary Table S2), because (1) this
interaction was not observed in the docking of PN-159 to claudin-5
with weaker total energy and (2) in claudin-3, where residue 68 is a
serine instead of aspartate in the ECL1, no binding afﬁnity was
measured and highly unfavorable docking energy was found.
Furthermore, the ability of PN-159 to disrupt the b-strands in ECLs
may contribute to the biological effect because the highest binding
and lowest total energy were observed for claudin-5, where b-
strands disappeared. Lower energy and/or binding was evident
when b-strands were fully or partially visible after peptide binding
in our modeling.
Comparison of the Efﬁcacy and Barrier Selectivity of the Peptides
Comparing the efﬁcacy of the 6 peptides, the following rank
order can be established on Caco-2 cells: 7-mer< C-CPE < AT-1002<
HAV-6 < ADT-6 << PN-159. This order is different on endothelial
barrier: C-CPE < HAV-6 < ADT-6 < 7-mer < AT-1002 << PN-159. The
Figure 6. Gene expression level of occludin and selected claudins in Caco-2 epithelial
and brain endothelial cells. NE, not expressed; OCC, occludin.
Figure 7. Afﬁnity measurements of the peptide PN-159 to full-length claudins (a) and binding curve for claudin-5-YFP (b). The association was measured by microscale ther-
mophoresis. Docking of PN-159 peptide to human claudin-1 (c) and human claudin-5 (d). Interacting residues are shown as sticks. Orange color: peptide PN-159; yellow color:
b-strands; purple color: a-helices of claudins. Membrane surface is marked by a solid black line. Kd, dissociation constant; YFP, yellow ﬂuorescent protein.
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TJ modulator effects of C-CPE, ADT-6, and HAV-6 were selective on
epithelial cells, which can be explained by the different claudin and
cadherin pattern between the epithelial and brain endothelial
models. In our previous study, major differences were demonstrated
between the BBB coculture and the Caco-2 models in their
cytoarchitecture, TJ structure, and claudin immunostaining.30 Caco-2
cells gave strong staining for claudins-1 and -4, whereas the prin-
cipal claudin in brain endothelial cells was claudin-5. These results
were strengthened by the present gene array data. The higher efﬁ-
cacy of 7-mer and AT-1002 peptides on endothelial cells are new
observations, and further studies would be needed to reveal the
molecular background.
For the in vivo application of TJ opening peptides, additional
interactions which may modulate their efﬁcacy must also be
considered, namely with the mucus layer of intestinal epithelium56
and the luminal glycocalyx of brain endothelium.57 In addition,
opening of paracellular junctions for drugs by peptides might also
result in enhanced transport of other molecules, xenobiotics, or
pathogens across the protective gastrointestinal barrier and BBB. In
case of the BBB, extravasation of serum proteins, like albumin, can
cause brain edema, which is a side effect of clinical BBB disruption
by hyperosmotic mannitol for the treatment of brain tumors.58
Size-selective opening of the BBB which would allow the passage
of small molecules but not that of serum proteins would be pref-
erable for potential clinical use. Because of these reasons, safety
assessment of TJ modulators must include testing for adverse re-
actions including edema formation and for potentially increased
microbial infections.1
Conclusion
All peptides tested showed a reversible TJ modulating effect and
were effective to open the paracellular pathway for the marker
molecules. We could demonstrate a selectivity of C-CPE, ADT-6, and
HAV-6 peptides for epithelial cells and 7-mer and AT-1002 peptides
for brain endothelial barrier. PN-159 was the most effective
modulator of junctional permeability in both models possibly
acting via claudin-1 and -5. Our results indicate that these peptides
can be effectively and selectively used as potential pharmaceutical
excipients to improve drug delivery across biological barriers.
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Table S1. The list of the studied genes. 
  Caco-2 BBB 
occludin OCLN Hs00170162_m1 Rn00580064_m1 
claudin-1 CLDN1 Hs01076359_m1 Rn00581740_m1 
claudin-2 CLDN2 Hs00252666_s1 Rn02063575_s1 
claudin-3 CLDN3 Hs00265816_s1 Rn00581751_s1 
claudin-4 CLDN4 Hs00533616_s1 Rn01196224_s1 
claudin-5 CLDN5 Hs01561351_m1 Rn01753146_s1 
claudin-7 CLDN7 Hs00600772_m1 Rn01496517_g1 
claudin-8 CLDN8 Hs00273282_s1 Rn01767199_s1 
claudin-9 CLDN9 Hs00253134_s1 Rn01460292_s1 
claudin-11 CLDN11 Hs00912957_m1 Rn01293260_m1 
claudin-14 CLDN14 Hs00273267_s1 Rn01407193_m1 
claudin-15 CLDN15 Hs00204982_m1 Rn02108734_s1 
claudin-16 CLDN16 Hs00198134_m1 Rn00590884_m1 
claudin-18 CLDN18 Hs00212584_m1 Rn01447445_m1 
claudin-19 CLDN19 Hs00381204_m1 Rn01416539_m1 
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Supplementary Fig. S1 
 
 
 
Cell viability assays after 1-hour treatment with tight junction modulator peptides at two 
concentrations. The toxicity of peptides on Caco-2 intestinal epithelial cells (a) and brain 
endothelial cells (b) was measured by MTT dye conversion assay and shown as percent of 
control (100 % viability). Values are presented as means ± SD, n=3-8. Statistical analysis: 
ANOVA followed by Dunnett’s test, p < 0.05 as compared with the control groups. 
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Supplementary Fig. S2 
 
 
 
Permeability of fluorescein across Caco-2 epithelial cell layers after 1-hour treatment with 
ADT-6, HAV-6 and C-CPE modulator peptides at concentrations of 1 and 2 mM. The 
apparent permeability coefficient (Papp) for fluorescein in the control groups was 0.28 ± 
0.04×10-6 cm/s. Values are expressed in the % of control group and presented as 
means ± SD, n=3-8. Statistical analysis: ANOVA followed by Dunnett’s test, p < 0.05 as 
compared with the control groups. 
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Supplementary Fig. S3 
 
 
 
Kinetics of peptide effects on the impedance of epithelial (a) and brain endothelial (b) cell 
layers. Values are presented as means ± SD, n=3-8. Statistical analysis: ANOVA followed 
by Dunnett’s test; p  <  0.05, significant differences in peptide-treated groups at 24 hour as 
compared with control groups. 
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Supplementary Fig. S4 
 
 
 
Effects of 24-hour treatment with scrambled peptides on Caco-2 epithelial cell viability. 
Data are shown as cell index in percentage of control group. Data are presented as means 
± SD, n=3-6. Statistical analysis: ANOVA followed by Dunett’s test. Statistically 
significant differences are p < 0.05, compared to control group. 
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Supplementary Fig. S5 
 
 
 
Permeability of Caco-2 cell layers for fluorescein (a) and albumin (b) after 1-hour 
treatment with scrambled peptides. Values of apparent permeability coefficients (Papp) in 
the control groups were for fluorescein: 0.27 ± 0.06×10-6 cm/s; for albumin: 0.17 ± 
0.02×10-6 cm/s.  
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Supplementary Fig. S6 
 
 
 
Docking of PN-159 peptide to human claudin-5 with weaker total energy as shown in 
Supplementary Table S2. Interacting residues are shown as sticks. Orange color: peptide 
PN-159; Yellow color: β-strands; purple color: α-helices of claudin-5. Membrane surface 
is marked by a solid black line. 
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Table S2. Table Docking energy components of PN-159 peptide to claudin 
monomers 
 Claudin-1 Claudin-3 
Claudin-5 
weaker stronger 
Elig -19.6 -9.86 -19.7 -13.58 
Eint -34.8 -66.8 -29.6 -35.6 
Etot -980.69 -881.54 -1014.16 -1076.53 
 
Abbreviations: Etot: total energy; Elig: ligand energy; Eint: interaction energy 
 
